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It has been postulated that essential hypertension develops
and is maintained by a natriuretic hormone which has its
effect through the inhibition of Na+K+ATPase. The work
contained in this thesis measured two characteristics of
this putative hormone; the ability to inhibit Na+K+ATPase
and cross-reactivity with digoxin antibodies.
Two different assays were developed for the measurement of
Na+K+ATPase activity and an extraction method was developed
in which inhibitory substances were isolated from plasma
according to their polarity, using Sep-Pak C^g cartridges.
Extracts, prepared from plasma samples from normotensive
and hypertensive subjects were measured for the capacity to
inhibit Na+K+ATPase and to cross-react with digoxin
antibodies. There was no significant difference between
the two populations and there was no correlation between
the inhibition and cross-reactivity or between blood
pressure and either activity.
Dilutions of extracts from bovine serum and from bovine
adrenal cortex cytosol produced dose-response curves for
both inhibition and cross-reactivity. When the extracts
were subjected to separation by high performance liquid
chromatography (HPLC), these activities eluted in several
fractions but inhibitory acivity and cross-reactivity co-
eluted in only two positions.
(vi)
The co-eluting fractions, obtained by HPLC separation of
adrenal cortex cytosol, did not contain non-esterified
fatty acids and could be steroid-like since they cross-
reacted with digoxin, Cortisol and corticosterone
antibodies. Trypsin reduced the activity of these
fractions by half and activity was not sensitive to heat
(80°C, 10 min). It was also shown that these fractions
stimulated steroidogenesis in isolated adrenal zona
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(a) Definition of hypertension
Epidemiological studies have shown that hypertension is
associated with an increase in cardiovascular mortality and
morbidity (Miall and Chinn, 1974; Dawber, 1980). The
value at which the blood pressure of an individual is
sufficiently raised for them to be described as
hypertensive is an entirely arbitrary decision since,
within a defined population, blood pressure is normally
distributed (Hawthorne, et al, 1974). Guidelines set out
by the World Health Organisation suggest values at which an
individual should be considered hypertensive and
consequently be treated with drugs to lower their blood
pressure. However, these values do not take account of
the increase in blood pressure with age which occurs in all
but a few societies (Freis, 1976), so it has been suggested
(Julius and Hansson, 1983) that the following values would
be more suitable for clinical use: normotensive; <140/90
at age 17 to 40, <150/90 at age 41 to 60 and <160/90 at age
>60, hypertensive; >160/95 at age 17 to 60 and >175/95 at
age >60. Borderline hypertension is defined as a blood
pressure between those of normotensive and hypertensive.
These values apply to non-pregnant adults only because
during normal pregnancy blood pressure decreases during the
first two trimesters rising to values close to normal
3.
towards the end of the third trimester (MacGillivray, et
al, 1969). In children, blood pressure values have been
reported to correlate better with height than age (Voors,
et al, 1978).
During the 1960's, the inheritability of hypertension was
the centre of a lively debate between Pickering and Piatt,
details of which can be found in Pickering's book: "High
Blood Pressure" (Pickering, 1968a). Pickering thought
that hypertension was due to many factors, inheritance being
only one of them. Piatt considered hypertension to be the
result of a single dominant gene and cited the bimodal
distribution of blood pressure within a population sample
as evidence in support of this idea. Reports of blood
pressure similarities between homozygous twins were also
taken as evidence in favour of the single gene theory.
However, the bimodal blood pressure distribution curves
were found to be a statistical artefact and the now
generally accepted view is that inheritance is only one of
several predisposing factors.
It has been reported that as many as 15% of the population
have high blood pressure (Hawthorne, et al, 1974) and in
95% of these cases no specific cause is found (Berglund, et
al, 1976) so the hypertension is described as "essential".
The term "essential" has historical roots (Pickering,
1968b), hypertension of this type is more correctly
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described as "primary". The term "essential" was used
because it was thought that the elevated blood pressure was
necessary to maintain perfusion of organs, especially the
kidney. In the remaining 5% of cases, it is possible to
detect the cause of the raised blood pressure so the
hypertension is described as secondary.
A list of the main causes of secondary hypertension is
given in Table 1.1. Most commonly secondary hypertension
is due to renal disease or renal vascular disease.
Hypertension in renal vascular disease is caused by
secondary hyperaldosteronism due to increased renin
secretion. Primary hyperaldosteronism, or Conn's syndrome
(Conn, 1955) is characterised by excess production of
aldosterone by either an adenoma or bilateral micronodular
hyperplasia. This condition is also characterised by a
low plasma renin, low plasma potassium but no increase in
ACTH secretion. The mineralocorticoid effects of
glycyrrhetinic acid, which is present in liquorice, cause
pseudo-hyperaldosteronism if liquorice is consumed in
sufficient quantities.
Excessive production of adrenal hormones causes secondary
hypertension in two other conditions; Cushing's syndrome
or disease (Cushing, 1932) and phaeochromocytoma. In
Cushing's disease the adrenal cortex produces increased
amounts of hydrocortisone which in the majority of cases is
5
TABLE 1.1
MAIN CAUSES OF SECONDARY HYPERTENSION
Diseases of the kidneys or urinary tract
e.g. glomerulonephritis, chronic pyelonephritis, renal
artery stenosis, renin secreting tumour.
Coarctation of the aorta
Phaeochromocytoma
Cushing's syndrome




- increased intracranial pressure
Drug associated conditions
- oral contraceptive pill, glucocorticoids,
carbenoxolone sodium, liquorice addiction
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due to inappropriate ACTH secretion by the pituitary gland.
Phaeochromocytoma is caused by a catecholamine-secreting
tumour of chromaffin tissue, occurring at any site along
the sympathetic chain, although 90% are located in the
adrenal gland.
(b) Prognosis and treatment of hypertension
(i) Mortality and morbidity
For many decades it has been known that raised blood
pressure is associated with increased mortality. Deaths
as a result of extremely high blood pressure (systolic
>180mmHg) are usually due to cerebral haemorrhage,
dissecting aneurysms or heart failure. However, the
majority of deaths due to hypertension are caused by
coronary artery disease and occur at lower pressures (140-
160mmHg systolic pressure) (Sleight, 1983).
Trials have shown that drug treatment of severe
hypertension (diastolic 115-129mmHg) improves mortality and
morbidity (Veterans Administration, 1967) and that
systematic control of blood pressure can reduce all-cause
mortality in subjects with diastolic pressures greater than
90mmHg (Hypertension Detection and Follow-up Program,
1979). Results from this latter trial suggested that mild
hypertensives would benefit from treatment. Analysis of
the results obtained for mild hypertensives (diastolic
7.
pressure 91-104mmHg) in the Veterans Administration trial
indicated that effectiveness of treatment depended on the
initial blood pressure and that treatment had the greatest
effect in patients with cardiovascular disease or who were
over 50 years old (Veterans Administration, 1972). The
value of treatment to the remaining patients was thought to
be questionable considering the side-effects of the
antihypertensive drugs. The Veterans Administration
trials were based on an extremely compliant group of
patients. Several recent studies on the treatment of mild
hypertension have been based on normal populations (MRC
Working Party, 1985; Australian National Blood Pressure
Study, 1980; Helgeland, 1980). All the studies concluded
that the incidence of cerebrovascular events was reduced in
treated subjects but there was disparity in the conclusions
about cardiovascular mortality. The MRC trial (1985)
reported a decreased incidence of all cardiovascular events
but no difference in the all-cause mortality rate. This
is in contrast with the Australian trial (1980) where there
was a decrease in mortality in the treated group with a two
thirds reduction in deaths due to cardiovascular disease.
The Oslo study (Helgeland, 1980) showed no difference in
cardiovascular morbidity between the treated and untreated
groups. The different conclusions reached in these trials
may be due to differences in patient selection and sample
size. The Australian trial comprised 3427 subjects, the
8
MRC trial 17354 subjects, whereas the Oslo study assessed
785 subjects.
(ii) Treatment of Hypertension
There are a large number of drugs available for the
treatment of hypertension (Table 1.2) which produce their
effect by a variety of different mechanisms many of which
are not clearly understood. Many of the early drugs are
no longer used for the chronic treatment of hypertension
because of their undesirable and, in some instances, life-
threatening side effects. This is particularly true of
ganglion blockers and adrenergic neurone blocking agents.
Centrally acting drugs such as cc-methyldopa and clonidine
are effective blood pressure lowering agents but their
usefulness is limited by their sedative effect. Direct
vasodilation was an attractive method for reducing blood
pressure but the drugs that have been developed have many
side effects which again limit their use. Vasodilators,
e.g. hydralazine, also need to be used in conjunction with
a diuretic and a /3-blocker to compensate for the fluid
retention and the increased sympathetic discharge.
The drugs most commonly used to treat hypertension are
diuretics and ^-blockers but they too have a number of
metabolic side effects which were recently highlighted in
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More recent additions to the list of drugs available are
the angiotensin converting enzyme inhibitors; captopril and
enalapril, and calcium channel blockers; e.g. nifedipine,
verapamil. Initially high doses of captopril were used to
treat hypertension and serious side effects were reported.
However, lower doses were found to be capable of
controlling blood pressure, thus reducing the incidence and
severity of the side effects. Calcium antagonists, as
they are known, inhibit the inward passage of calcium ions
across myocardial and vascular smooth muscle cell
membranes.
All of the drugs have undesirable side effects to a greater
or lesser degree and it is the balance between the possible
benefits of treating moderately raised blood pressure and
the side effects of the treatment which is currently under
debate. Although antihypertensive drugs reduce blood
pressure they do not produce their effect by treating the
cause of the hypertension, with the possible exception of
the calcium blockers. It will not be possible to produce
drugs which specifically treat the cause(s) of essential
hypertension until it is known how essential hypertension
develops and is maintained.
2. SALT AND HYPERTENSION
The reduction of salt intake in hypertensives as a method
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of reducing blood pressure has been a subject of great
interest especially since there are a large number of
borderline hypertensives in whom the benefits of drug
treatment may be outweighed by the side-effects of the
drugs. Prior to the development of anti-hypertensive
drugs it was possible to treat severe hypertension by salt
restriction. It was shown that by drastic reduction of
the sodium intake to 5-10mmol/day it was possible to lower
the blood pressure in patients suffering from hypertension
(Kempner, 1948). Unfortunately this diet of rice and
fruit is notorious for being extremely unpalatable and so
it is difficult for patients to comply. When the salt
intake was increased to 25-35mmol/day the blood pressure
rose but not to the pretreatment levels (Watkin, et al,
1950). Kawasaki, et al, (1978) have suggested that there
is a sub-group of essential hypertensives who are salt-
sensitive in an analogous way to the Dahl salt-sensitive
rats. They found that some patients responded to a low
sodium diet (9mmol/day) by a significant reduction in blood
pressure while others did not. The salt-sensitive group
had higher blood pressures when on an average (lOOmmol/day)
and high (240mmol/day) sodium diet. No difference in
blood pressure was observed between the average and high
sodium diets and it should be noted that the sodium content
of the "average Western" diet lies between the values
chosen by Kawasaki, et al, as average and high.
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Studies on moderate dietary salt reduction in subjects with
hypertension have shown it has a small (approx. 7mmHg) but
statistically significant effect on blood pressure
(MacGregor, et al, 1982/ Morgan, et al, 1978). Although
anti-hypertensive drugs resulted in a greater reduction in
blood pressure, the decrease due to moderate salt
restriction was sufficient in many patients to reduce the
blood pressure to within the normal range (Morgan, et_ al,
1978). It has been pointed out (Laragh and Pecker, 1983)
that essential hypertension is not a homogeneous entity and
that salt restriction could be of therapeutic use in
selected patients e.g. low renin hypertensives, but would
not be universally effective. This is in agreement with
the suggestion of Kawasaki, et al, (1978) that there is a
sub-group of essential hypertensives who are salt-sensitive.
The importance of salt intake in the development of
hypertension has been a subject of great debate (Proc. Int.
Soc. Hypertension, 1979). It is largely agreed that
extremely high salt intakes are associated with a high
incidence of hypertension. For example, in populations
such as that found in north-east Japan, where the daily
consumption of salt was around 400mmol, blood pressure and
death from apoplexy was higher than in other regions of
Japan (Sasaki, 1964). Death due to apoplexy was assumed
to reflect death as a result of intracranial haemorrhage,
although apoplexy can also be due to intracranial
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thrombosis. The daily salt intake of the average
"Western" diet is 150-200mmol and the current debate is
whether the population at large would benefit from a
moderate reduction in salt intake.
In "Western" societies hypertension is relatively common
and blood pressure increases with age. Studies of
"primitive" societies have shown that salt intake is much
lower, the incidence of hypertension is low or absent and
blood pressure does not increase with age (Freis, 1976).
It has been proposed that the difference in incidence of
hypertension between these two types of society is due to
the increased salt intake in the "Western" societies since
"primitive" societies which consume large quantities of
salt also develop high blood pressure. These observations
on the "primitive" societies are at the centre of the
debate about salt and hypertension. Simpson (1979) is one
author who has pointed out that there are other differences
between the societies, including the overall composition of
the diet, which could be responsible for the different
levels of blood pressure.
The diet of "primitive" populations is not only low in
sodium but also high in potassium. It has been suggested
that the lack of hypertension in these societies is due to
the increased potasssium intake. The effects of dietary
potassium on blood pressure are complicated (Tannen, 1983);
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potassium depletion lowers blood pressure in normotensive
and hypertensive animals but a high potassium intake has no
effect on normotensives but lowers blood pressure in
hypertensives. However, a recent large population study
reported that there was a negative correlation between
urinary potassium excretion and blood pressure (Intersalt
Cooperative Research Group, 1988). Another cation which
has been implicated in the development of hypertension is
calcium (McCarron, 1985), the importance of this cation has
been debated (MacGregor, 1985).
Other dietary alterations which have been shown to have
blood pressure lowering effect include a vegetarian diet
(Rouse, et al, 1983; Margetts, et_ a_l, 1986) and
supplementation of the diet with polyunsaturated fats
(Puska, et al, 1983) or linoleic acid (Comberg, et al,
1978). High alcohol consumption (Saunders, 1987) and
obesity (Chiang, et_ al, 1969) are also associated with
hypertension and a recent study indicated that these
variables were more strongly related to blood pressure than
urinary sodium excretion (Intersalt Cooperative Study
Group, 1988).
3. HYPOTHESISED CAUSES OF ESSENTIAL HYPERTENSION
Many different theories have been proposed to explain how
essential hypertension develops and is maintained. The
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physiology of blood pressure control is complex depending
on the inter-relationship of several different endocrine
and nervous systems. As discussed below, abnormal
functioning of normal control systems could be responsible
for the increased vasoconstriction observed in essential
hypertension which is the only universal difference between
normotensives and essential hypertensives. It is now
generally accepted that essential hypertension is a
multifactorial condition and as such it is likely that
there are several different causes or a combination of
predisposing features.
The heterogeneous nature of essential hypertension should
not preclude the investigation of these subjects for the
presence of a single factor which may be present only in a
sub-group which is characterised by a common defect e.g.
inability to deal effectively with a salt load. Within
the group of patients described as essential hypertensives
it is likely that there are several sub-groups whose
hypertension may arise by the mechanisms described in the
theories outlined below.
Brown and Macquin (1981) suggested that intermittent raised
secretion of adrenaline from the adrenal medulla
accumulates in sympathetic nerve endings and when released
acts at pre-synaptic^-receptors thus increasing
noradrenaline release. This in turn stimulates the
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activity of the sympathetic nervous system leading to
increased vasoconstriction and blood pressure. 78 studies
of plasma levels of catecholamines in normotensives and
hypertensives were surveyed and, although most studies
reported increased levels in hypertensives, the difference
between the two populations was significant in only 40% of
the studies (Goldstein, 1983). Goldstein noted the
problems encountered when trying to measure catecholamines;
careful collection of blood samples was essential in order
to avoid oxidation of catecholamines and the avoidance of
stress, caffeine and high salt was also important.
Goldstein also reported that when total catecholamines were
measured hypertensives always had significantly higher
levels but that noradrenaline and adrenaline were raised
independently of one another. It would be expected from
Brown and Macquin's theory that levels of both
catecholamines would be increased in parallel.
An alternative hypothesis suggests that idiopathic
hyperaldosteronism (IHA) is actually an extreme variant of
essential hypertension (EHT) and not a variant of Conn's
syndrome (Padfield, et al, 1981). Low renin is a feature
of Conn's syndrome but is also present in 25% of essential
hypertensives (Dunn and Tannen, 1974). Electrolyte
abnormalities and angiotensin II (All) responsiveness were
more similar to EHT than Conn's syndrome and Padfield, et
al, suggest that IHA is in fact a subset of EHT and that
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there is a wider than normal range of aldosterone
concentrations in EHT.
Since infusion of prostaglandins (PGE2 and PG^)^ into the
renal artery, have been shown to decrease blood pressure
(Baer and McGiff, 1979) and cause natriuresis (Jones, et
al, 1981) it is possible that hypertension could result
from inadequate renal production of these prostaglandins.
Decreased production of PGE2 has been reported in both
primary and secondary hypertension (Sato, et_ al, 1983) but
Rathaus, et a_l (1983) reported decreased production in low
renin EHT but not in normal renin EHT. At present, it is
not clear whether lower levels of natriuretic
prostaglandins are responsible for, or a consequence of,
hypertension.
The failure to mobilise renal dopamine in response to a
saline load was observed in essential hypertensives
(Perkins, el: al, 1980) and, since dopamine is a potent
natriuretic agent (Lee, 1982), it has been suggested (Lee,
1981) that this could be a cause of essential hypertension.
In the natriuretic hormone hypothesis (de Wardener and
MacGregor, 1980), it is postulated that essential
hypertension develops and is maintained by an entirely
novel compound which acts as an endogenous Na+K+ATPase
inhibitor. The stimulus for release of this inhibitor is
central volume expansion which is a consequence of a
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primary renal defect characterised by failure to cope with
a salt load. The primary renal fault could be failure to
mobilise renal dopamine.
In 1981, de Bold, et al, reported that intravenous
injection of rat atrial homogenate, into control rats,
produced both a natriuresis and diuresis. This spawned a
field of research which advanced at such a pace that by
1984 the substances responsible, the atrial natriuretic
peptides, had been purified, sequenced and the gene cloned
in both rat (Yamanaka,et al, 1984) and man (Oikawa,et al,
1984). The physiological role of the atrial natriuretic
peptides has yet to be elucidated but they are likely to
have an important role in the fluid balance of the body.
Extensive reviews can be found in the following -sources;
Genest, 1986, Needleman and Greenwald, 1986, Maack, et al,
1985. It has been apparent for some time that the
natriuretic peptides were not the putative natriuretic
hormone of de Wardener and MacGregor (1 980) since it was
shown that they did not inhibit Na+K+ATPase (Thibault, et
al, 1983).
4. THE NATRIURETIC HORMONE
In this thesis the natriuretic hormone hypothesis was
investigated by examining plasma and serum for the presence
of endogenous Na+K+ATPase inhibitors. Work which led to
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the development of the hypothesis, the investigation of the
hypothesis and related work were extensively reviewed
recently by de Wardener and Clarkson (1985). Since work
on endogenous Na+K+ATPase inhibitors has advanced in
parallel with work in this thesis, this section will only
review literature which had been published before the
commencement of this thesis in order to present an idea of
the state of the field at the outset of this work.
(a) Involvement of a humoral factor in the natriuresis of
volume expansion.
Originally essential hypertension was thought to be
associated with volume expansion and consequently a large
amount of effort was directed towards the investigation of
the natriuresis of extracellular fluid volume expansion.
In 1961, de Wardener, et al, demonstrated that a humoral
factor was responsible for the natriuresis following volume
expansion in the dog. When two dogs were cross-circulated
(parabiosed), volume expansion of one dog resulted in
natriuresis in both dogs, although the natriuresis in the
recipient dog was 3 to 10 times less. Pearce, et al,
(1969) showed that the natriuretic response to volume
expansion was exaggerated in DOCA-salt treated rats and
depressed,in salt deficient rats. When these rats were
cross-circulated the response of the salt deficient rats
was restored without altering the response of the DOCA-salt
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rats which indicated that a humoral factor, produced by the
DOCA-salt rat, was responsible for the natriuretic
response. Another hypertensive rat model, the Dahl salt-
sensitive rat, develops hypertension when fed a high salt
diet. Dahl, et al, (1967) parabiosed salt-sensitive and
salt-resistant rats and noted that the blood pressure of
both rats increased when fed on a high salt diet. It was
suggested that the hypertension developed in the salt-
resistant rat as a consequence of a humoral factor produced
by the salt-sensitive rat.
The onset of natriuresis of volume expansion was examined
by Pearce, et_ al, (1974) using cross-circulated rats where
one rat was volume expanded using whole blood. The
natriuresis was of gradual onset taking 60 to 80 minutes to
reach a peak. Since infusing the donor rat for one hour
before cross-circulating with the recipient did not affect
the rate of onset of natriuresis, the natriuretic effect of
volume expansion was not due to substances present in the
infused blood. No significant natriuresis was observed if
the donor was not expanded which suggested that an
endogenous substance was responsible.
Extracts have been prepared from the plasma of volume
expanded subjects in an attempt to isolate the humoral
factor (s) responsible for the natriuresis. Extracts from
the plasma of volume expanded cows (Lichardus, et al,
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1968), dogs (Buckalew and Nelson, 1974) and rats (Pearce
and Veress, 1974) have been demonstrated to be natriuretic
in assay rats. The natriuretic activity present in volume
expanded rat plasma was fractionated on Sephadex G-50
(Pearce and Veress, 1974) and it was observed that only a
large molecular weight fraction from the volume expanded
rat plasma had a greater natriuretic capacity than the
control rat.
Central volume expansion of human volunteers, by water
immersion up to the neck, resulted in a significant
natriuresis and an increase in the natriuretic fraction
extracted from urine (Epstein, et al, 1978).
It was hypothesised that volume expanded hypertension was
due to a factor which inhibited Na+K+ATPase (Haddy and
Overbeck, 1976) so the plasma of volume expanded
experimental animals has been investigated for the presence
of Na+K+ATPase inhibitory capacity and it has been shown
that chromatographic separation produces several active
fractions. Gonick, et al., (1977) found six peaks of
inhibitory activity on gel filtration of plasma on Sephadex
G-25 but only one peak contained significantly greater
activity than the control plasma. HPLC separation of
plasma on cation exchange and reverse-phase octadecylsilane
columns revealed two peaks capable of both Na+K+ATPase
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inhibition and cross-reacting with digoxin antibodies
(Gruber, et ad, 1980). These two peaks were present in
increased amounts in volume expanded dogs.
Plasma extracts from volume expanded rats, prepared by HPLC
separation, exhibited antinatriferic activity (Bealer, et
al, 1983). Antinatriferic activity is defined as the
inhibition of sodium transport across anuran membranes,
assessed by a decrease in the short circuit current.
Buckalew and Nelson (1974) reported that ultrafiltrates of
plasma from volume expanded dogs had a greater capacity to
inhibit the toad bladder short circuit current than that of
volume depleted dogs. However, although Buckalew (1975)
was able to repeat these findings Brown, et al, (1974),
using the same ultrafiltration method, were not.
(b) Effect of sodium intake on Na~t"K+ATPase inhibitor levels
The effect of altering sodium levels on the circulating
concentration of endogenous Na+K+ATPase inhibitors has been
investigated using a cytochemical method to measure
inhibition. In this method inhibition of Na+K+ATPase is
measured as a stimulation of glucose-6-phosphate
dehydrogenase in tissue slices as assessed using
densitometric measurement of the colour produced by the
reaction of the dehydrogenase with a dye (Fenton, et al,
1982). Using this assay, de Wardener, et ad, (1981) and
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MacGregor, et al, (1981) showed that the ability of plasma
to stimulate glucose-6-phosphate dehydrogenase increased
with an increase in sodium intake. The glucose-6-
phosphate dehydrogenase stimulating capacity of a
hypothalamic extract has also been shown to increase when
rats are fed a high salt diet (Alaghband-Zadeh, et_ al/
1983) .
(c) Demonstration of an inherited kidney defect in
genetically hypertensive rats.
Results from kidney cross-transplantation experiments in
genetically hypertensive rats have demonstrated that the
kidneys are involved in the development of hypertension in
these rats.
Bianchi, et al, (1974) selectively bred a rat model of
essential hypertension which was normotensive at birth but
which became hypertensive as it matured. These rats were
described as spontaneously hypertensive rats (SHR). When
kidneys were transplanted between SHR and normotensive rats
the recipients of the kidneys from SHR rats developed
hypertension irrespective of the original strain and the
recipients of the kidneys from the normotensive rats
remained or became normotensive (Bianchi, et al, 1974).
This demonstrated that hypertension could develop in a
normal rat if it was the recipient of a genetically
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defective kidney. These experiments were performed on
adult rats who were already hypertensive. When the cross-
transplants were carried out on immature rats, prior to the
development of hypertension in the SHR, the same results
were obtained indicating that the development of
hypertension in these rats was due to a genetic defect in
the kidney and not due to kidney damage as a result of the
raised blood pressure.
Dahl, et ad, (1962) selectively bred two strains of rat
which were described as hypertension-resistant and
hypertension-prone. The hypertension-prone rats became
hypertensive on a high salt diet and are often referred to
as salt-sensitive, the hypertension-resistant rats being
described as salt-resistant. It was observed that, when
kidneys were cross-transplanted between the strains, the
recipients of the kidneys from the hypertension-prone rats
became hypertensive irrespective of the recipient's strain
(Dahl and Heine, 1975). Transplantation of a kidney from
a hypertension-resistant rat resulted in a blood pressure
similar to that of control rats.
(d) Source of circulating inhibitor
Kaloyanides, et ad, (1977) performed organ ablation
experiments and found that the natriuretic response to
volume expansion was lost by decapitation but not by
25
thyroparathyroidectomy, hypophysectomy or adrenalectomy
leading them to suggest that the natriuretic factor was
produced in the brain. The anteroventral third ventricle
(AV3V) of the rat brain is critical for normal fluid-
electrolyte regulation and cardiovascular homeostasis. It
has been shown that the natriuretic response of AV3V-
lesioned rats to volume expansion with saline is attenuated
when compared with control rats (Bealer,et al, 1983) and
that AV3V-lesioned rats no longer respond to DOCA-salt
treatment with an increase in blood pressure (Songu-Mize,
et al, 1982). When different tissues of the rat were
analysed for the presence of substances capable of
stimulating glucose-6-phosphate dehydrogenase only the
hypothalamic extract contained any activity (Alaghband-
Zadeh, et al, 1983). These results suggest that the
source of the circulating inhibitor could be the AV3V
region of the brain, specifically the hypothalamus.
However, it has been reported that digoxin-like
immunoreactivity was present in the adrenal gland of rat
(Schreiber, et al, 1981a) and of the rabbit (Schreiber, et
al, 1981b). This immunoreactivity could be due to cross-
reactivity of known adrenal steroids with antibodies to
digoxin. If further investigation demonstrated that the
adrenal gland contained a factor, or factors, which was
capable of inhibiting Na+K+ATPase, as well as cross-
reacting with digoxin antibodies, a novel factor produced
in the adrenal gland, and possibly under hypothalamic
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control, could be responsible for the immunoreactivity
which has been measured.
(e) Extraction and purification of cardiac glycoside-like
substances
Several different sources have been investigated for the
presence of endogenous cardiac glycoside-like activity.
Measurement of activity has employed one or several of the
following assays; inhibition of Na+K+ATPase,
antinatriferic activity, cross-reactivity with antibodies
to cardiac glycosides, displacement of tritiated ouabain
from its binding site on erythrocytes, inhibition of ion
fluxes from blood cells.
When plasma, urine or tissue are subjected to extraction
and purification methods the production of artefacts
becomes a serious consideration. All starting materials
have the capacity to produce artefacts, whether it is body
fluids or tissue, due to the presence of e.g. ions,
hormones, fatty acids, which, if sufficiently concentrated,
will interfere in assays for cardiac glycosides. For this
reason it is necessary to use as many assays as possible,
each depending on different properties of the factor. In
practice the quantity of the extract and, to a lesser
extent, financial and time constraints determine the number
of assays used to test the extract. Problems with
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artefacts can also be reduced by attempting to specifically
remove substances during the isolation procedure which are
known to interfere in assays. The use of cultured cells
has been advocated as a possible way of avoiding the
contamination of starting material with undesirable
substances and avoiding problems associated with artefacts
arising from the effects of extraction techniques on normal
plasma or tissue constituents (Mir, et al, 1987). The
extent of the problem with artefacts varies depending on
the nature of the starting material, the concentration
factor, the extraction method and the assays used.
(i) Plasma
Chromatographic separation of plasma and serum has
demonstrated that several active fractions are present.
HPLC separation of plasma from volume expanded dogs
produced two peaks of co-eluting Na+K+ATPase inhibition and
digoxin cross-reactivity which were present in higher
concentrations than in the plasma of hydropenic dogs
(Gruber, et al, 1980). Extracts prepared by HPLC of
volume expanded rat plasma contained antinatriferic
activity in control rats but not in AV3V-lesioned rats
(Bealer, et al, 1983). Anion exchange chromatography of
plasma produced three peaks capable of Na+K+ATPase
7 ....
inhibition and inhibition of [H]-ouabain binding in nearly
half of the normotensives and all of the hypertensives
studied (Cloix, et al, 1983).
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(ii) Urine
A urine extract prepared by gel filtration on Sephadex G-25
was natriuretic (Bougoignie, et al, 1974), antinatriferic
(Kaplan, et al, 1974) and capable of inhibiting sodium
transport in the isolated rabbit collecting tubule from the
peritubular but not from the luminal surface (Fine, et al,
1976). Only the extract prepared from the urine of
uraemic patients was endowed with these characteristics.
A similar extract was prepared by Poston, et al, (1982).
Normotensive volunteers were given 9oc-fluorocortisol until
they underwent natriuresis and escaped from the salt
retaining effect of the mineralocorticoid; so called
mineralocorticoid escape. Post-escape urine extract from
these volunteers significantly inhibited the ouabain-
sensitive sodium efflux rate from leucocytes but pre-escape
urine did not.
(iii) Tissue extracts
Endogenous cardiac glycoside-like activity has been
reported in extracts from guinea pig brain (Fishman, 1979),
rat brain (Lichtstein and Samuelov, 1980), bovine
hypothalamus (Haupert and Sancho, 1979) and rat
hypothalamus (Alaghband-Zadeh, et al, 1983). Each of the
investigations used different assays for the assessment of
activity but all used acetone extraction which has been
demonstrated to produce artefacts (Whitmer, et al, 1982).
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It has also been reported that acetone-HCl extraction of
guinea pig heart produced non-specific irreversible
inhibitors of Na+K+ATPase but that aqueous extraction
produced a specific inhibitor which was also capable of
inhibiting [JH]-ouabain binding (De Pover, et al, 1982).
Digoxin-like immunoreactivity was found in extracts from
rat adrenal glands by Schreiber, et al, (1981a) using
acetone and organic solvent extraction. Thin layer
chromatography separation showed that several fractions
were responsible for the immunoreactivity.
Using gel filtration on Sephadex G-25 followed by
polyacrylamide gel electrophoresis, Raghaven and Gonick
(1980) extracted a fraction from the kidneys of volume
expanded rats which was antinatriferic and would inhibit
Na+K+ATPase. The rationale for this approach was that if
volume expansion increased the concentration of the
inhibitor then more would be bound to the receptors in the
kidney so the kidney could provide an enriched source.
(iv) Amphibian plasma and skin
Since the poison glands in the skin of the toad, Bufo
marinus, contain a cardiac glycoside-like substance, Flier
(1978) prepared extracts from the skin of Bufo marinus and
two other species of toad. Although the other two species
of toad did not have poison glands on their skin, extracts
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from all three species contained comparable amounts of
activity which was measured as inhibition of Na+K+ATPase,
inhibition of ^K+influx into erythrocytes and inhibition
O
f # ...
of [H]-ouabain binding. Purification of skin extracts
from four species of toad identified the active substances
in two species; Bufo and Atelopus, as bufodienolides and
in the other two species; Dendrophyryniscus and
Melanophryniscus, the active substances were more polar and
of unknown structure (Flier, et al, 1980). In the same
paper, skin extracts from over thirty species of frog were
reported to contain low levels of ouabain-like compounds.
Flier, et al, (1980) suggest that the ouabain-like
substances may be present not only as a means of defence
but also as physiological regulators of Na+K+ATPase since
amphibian skin is important for sodium and water
homeostasis in these species and the skin is rich in the
enzyme. Plasma from the toad, Bufo marinus, was shown to
"3
contain substances which inhibited the binding of [ H]-
ouabain to human erythrocytes (Flier, et al, 1979) but
both plasma and skin from the frog, Rana pipiens, lacked
activity. Toad plasma was also capable of cross-reacting
in a digoxin RIA and preincubation of the toad plasma with
anti-digoxin or anti-ouabain antibodies prevented the
*3
,
plasma from inhibiting [H]-ouabain binding to
erythrocytes. Since Bufonid erythrocytes were incapable
of binding ouabain, the toad would be expected to be immune
to the effects of this endogenous ouabain-like compound.
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(f) Involvement of endogenous Na+K+ATPase inhibition in
uraemia
Cardiac glycoside-like activity has been reported in plasma
and urine of patients with uraemia, a condition which is
often associated with expansion of the extracellular fluid
volume.
It has been known for some time that there are ion
transport abnormalities associated with uraemia. These
have been measured as a decrease in ouabain-sensitive
Na+K+ATPase activity in erythrocyte membranes (Cole, 1973)
and a decrease in sodium efflux from leucocytes (Edmondson,
et al, 1975a). It has also been reported that there is a
decrease in Na+K+ATPase activity in intestine (Kramer, et
al, 1974) and in brain (Minkoff, et al, 1972) in
experimental uraemia. A humoral factor was implicated
when it was reported that the sodium efflux of control
erythrocytes decreased when they were incubated in uraemic
serum (Kramer, et al, 197 6) and that there was significant
inhibition of normal brain Na+K+ATPase by uraemic serum
(Minkoff, et al, 1972). It was subsequently reported that
the results for digoxin levels in two out of seven patients
with renal failure receiving digoxin could vary from 0.3-
3ng/ml depending on which digoxin Jcit was used to measure
the values (Belpaire, 1975). Similar results were
reported by Graves, et. al, (1983) who measured digoxin
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levels in patients with renal failure who were not
receiving digoxin and noted that more than 60% had false
positive values in most assays. Samples showing cross-
reactivity were not tested for the ability to inhibit
Na+K+ATPase.
(g) Involvement of endogenous Na+K+ATPase inhibition in
hypertension
Sodium transport in hypertension has been studied in intact
cells and using extracts of plasma and urine.
Comparing normotensive and hypertensive dogs, Overbeck, et
ft fi
al, (1976) observed that the ouabain-sensitive Rb uptake
of small mesenteric arteries and splanchnic veins from
hypertensive dogs was depressed when they were incubated in
the dogs own plasma. Since ouabain-sensitive ^Rb uptake
is considered to be a direct function of the transport
activity of Na+K+ATPase, this suggests that the enzyme is
inhibited in hypertensive dogs.
The sodium content of leucocytes has been shown to be
higher in hypertensive subjects and was associated with a
decreased rate constant for sodium efflux (Edmondson, et
al, 1975b). Poston, et al, (1981) observed that sodium
transport was impaired in both erythrocytes and leucocytes
from hypertensives. A humoral factor would appear to be
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responsible for this since incubation of leucocytes from
normotensives in serum from hypertensives resulted in
sodium transport which was impaired to the same degree as
hypertensives (Poston, et al, 1981).
A raised internal sodium concentration has also been
observed in lymphocytes from hypertensives and from the
normotensive relatives of hypertensives (Ambrosioni, et al,
1981) . In the essential hypertensives the lymphocytic
sodium concentration significantly correlated with
systolic, diastolic and mean blood pressure. There was no
such correlation with blood pressure in the normotensives.
Ouabain-sensitive sodium efflux rates in leucocytes were
also reported to be lower in normotensive subjects who had
one or more first degree relative with essential
hypertension than in normotensive subjects with no such
family history (Heagerty, et al, 1982). It was suggested
that, since blood pressure was normal in these subjects, a
reduction in ouabain-sensitive sodium efflux was not
directly involved in hypertension. Subsequent editions of
the Lancet contained letters arguing against this
interpretation and replies from Heagerty, et al, which
demonstrate the lack of agreement on this point which
prevailed in this field at the outset of this work. It
was argued that a primary genetic abnormality, measured as
a decrease in sodium efflux, may not produce hypertension
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for many years or may require an environmental trigger
e.g. salt intake. Other correspondents pointed out that
there was a body of literature which indicated that a
humoral factor was responsible for the reduced Na+K+ATPase
activity.
Hamlyn, et ad, (1982) found that the ability of
deproteinised plasma to inhibit Na+K+ATPase was correlated
with mean arterial pressure in the hypertensives but not in
the normotensives. However, when the normotensives were
included in the statistics a greater correlation
coefficient was obtained. Hamlyn, et al, (1982) also
measured the cross-reactivity of their plasma extracts with
digoxin antibodies and found no correlation between the
amount of inhibition and the amount of cross-reactivity.
However, Gruber, et ad, (1982) observed a correlation
between digoxin cross-reactivity and systolic and diastolic
blood pressure in experimentally induced hypertension in
monkeys.
It has also been reported that injection of digoxin
antibodies into DOCA-salt hypertensive rats lowers their
blood pressure (Kojima, et al, 1982).
(h) The natriuretic hormone hypothesis.
Results from parabiosis experiments between salt-sensitive
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and salt-resistant rats led Dahl, et ad, (1967) to suggest
that a humoral factor was responsible for the sustained
rise in blood pressure in the salt-sensitive rats fed a
high salt diet. This hypothesis was extended by de
Wardener and MacGregor (1982) to explain how a natriuretic
hormone, which acts by inhibition of Na+K+ATPase, could be
responsible for the development and maintenance of
essential hypertension.
In the natriuretic hormone hypothesis it is postulated
that, in essential hypertension, there is an inherited
kidney defect which is characterised by an inability to
excrete sodium. The accumulation of sodium and water
which results from this produces an increase in the
intrathoracic blood volume which stimulates the release of
a Na+K+ATPase inhibitor, possibly from the hypothalamus.
The Na+K+ATPase inhibitor acts on the nephron to produce
natriuresis but also acts on peripheral blood vessels
resulting in vasoconstriction and so a central increase in
blood volume which in turn stimulates further release of
the natriuretic hormone. Inhibition of the Na+K+ATPase
results in an increase in sodium concentration inside the
cell so there is no electrochemical gradient to drive the
sodium-calcium exchange (Blaustein and Hamlyn, 1983).
Increased intracellular calcium would lead to increased
muscle contraction and so to increased vascular resistance.
Cardiac glycosides have been shown to increase sensitivity
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of smooth muscle to vasoconstrictive agents (Brender, et
al, 1970) which is another mechanism by which the
natriuretic hormone could increase venous tone.
5. AIM OF THE THESIS
The aim of this thesis was to develop a method for
extracting and measuring endogenous Na+K+ATPase inhibitory
activity, which could be used on a 10ml blood sample, and
to use this method to investigate the hypothesis that an
endogenous Na+K+ATPase inhibitor was present in human
plasma in increased quantities in hypertensive subjects.
Furthermore, the capacity of the inhibitor to cross-react
with digoxin antibodies was to be measured. It was hoped
that it would be possible to further investigate the





1. GENERAL REAGENT PREPARATION
A list of reagents used and their suppliers can be found in
Appendix I. Enzymes, radio-labelled compounds and
immunological reagents are included in this list. All
reagents were of analytical grade.
The composition and preparation of buffers and reagent
solutions are given in Appendix II.
2. PREPARATION AND STORAGE OF SPECIMENS FOR ANALYSIS
(a) Blood Samples
Blood samples from individuals were collected into lithium-
heparin tubes. Plasma was separated by centrifugation
(1500 x g, 20°C, 10 min) and stored at -20°C.
Samples from normotensive and hypertensive individuals were
kindly provided by Dr C.G. Wathen, Department of Medicine,
R.I.E.. Blood (10-20ml) was collected from newly
diagnosed essential hypertensives who had never received
any antihypertensive medication. Samples to be used as
controls were obtained from hospital out-patients suffering
from minor complaints and from volunteers; neither of
these groups was on medication.
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Polycythaemia is characterised by an excess of red blood
cells and treatment of this condition often includes
removal of relatively large quantities of blood. A large
quantity of plasma was collected from a single
polycythaemic patient who was also suffering from
hypertension. Pooled serum collected from several
patients suffering from polycythaemia was obtained from the
Blood Transfusion Service.
Bovine blood, obtained in large quantities from the local
abattoir, was collected into plastic containers (21) and
left at room temperature to allow it to clot. After the
blood had coagulated and the clot retracted, the liquid
surrounding the clot was centrifuged for 10 minutes (1500 x
g, 20°C) and the serum separated and stored at -20°C until
required. The colour of the serum indicated that there
had been substantial haemolysis of the red blood cells.
(b) Bovine Adrenal Glands
Fresh bovine adrenal glands were collected onto ice and
transported from the abattoir to the laboratory as quickly
as possible (<30min). When the glands were to be used for
the preparation of isolated cells they were transported in
ice-cold normal saline (0.155M). The protocol for the
preparation of cytosol from bovine adrenal cortex is given
in Appendix III.
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3. MEASUREMENT OF Na+K+ATPase ACTIVITY
In order to measure Na+K+ATPase inhibition, an assay was
set up to measure the activity of the enzyme. Initially,
an assay was used which depended on the colorimetric
determination of phosphate produced by the hydrolysis of
adenosine 5'-triphosphate (ATP). Subsequently, an enzyme-
linked method was adapted for use on a Cobas FARA
centrifugal analyser (Roche Diagnostics, Welwyn Garden
City, U.K.).
(a) Colorimetric measurement of phosphate produced by ATP
hydrolysis
This method comprised two parts; Na+K+ATPase incubation
followed by the colorimetric measurement of phosphate
released during the incubation.
By decreasing the enzyme concentration and increasing the
incubation time proportionately, sensitivity was improved
because the ratio of inhibitor to enzyme was increased and
so the inhibitor would bind to a greater proportion of the
total enzyme available producing more inhibition for a
given inhibitor concentration. Assay conditions ranged
from 6.25 x 10~^U/1 enzyme incubated for 16hr to 75U/1
incubated for lhr.
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75Ctyil imidazole buffer (pH7.8; Appendix II), lOCtyul ATP
(200mM) and 50pl sample were pre-incubated for 10 minutes
at 37°C. The incubation was started by adding lOO^pl
Na+K+ATPase (dog kidney; 62.5-750U/1). After 1-16 hours
lml of ice-cold 0.61M trichloroacetic acid (TCA) was added
and 50^1 portions of the mixture were taken for measurement
of phosphate.
To correct for endogenous phosphate in the sample and
enzyme-independent hydrolysis of ATP, controls were
included with each assay batch. Three different controls
were prepared; either ATP or ATPase were omitted or
ATPase was added after the incubation had been terminated
by the addition of lml TCA (0.61M). All control tubes
contained buffer in place of sample.
In order to quantify the inhibition a standard curve was
prepared using known concentrations of ouabain in place of
sample in the incubation mixture. Ouabain standards were
prepared in lOmM imidazole buffer (pH7.8; Appendix II) by
diluting 2mmol/l ouabain to give 12 standards ranging from
0.005-25jumol/l.
Phosphate generated in the enzyme incubation was measured
using a method based on that of Baginski and Zak (1960).
This was a colorimetric method in which a phosphomolybdate
complex was reduced by ascorbic acid to produce a blue
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colour. Any free molybdate that remained was complexed by
arsenite-citrate reagent.
Sample (50^il) was added to 1ml 0.61M TCA and incubated at
room temperature for 10 minutes. After centrifugation
(2800 x g, 3 min, 4°C), 500^1 of the supernatant was added
to lOOjul 0.57M ascorbic acid. To this 250^ul 8.1mM
ammonium molybdate was added followed by 500pl arsenite-
citrate reagent (Appendix II). After 15 minutes the
absorbance was read at 700nm using a Pye-Unicam SP8-100
UV/Vis spectrophotometer (Cambridge, U.K.) .
Phosphate concentrations were obtained by comparing the
absorbance with a phosphate standard curve. Standards
(0.07-5mM) were prepared by serial dilution of 0.5M
potassium phosphate in 0.61M TCA. These covered a working
range of l-88yumol/l in the reaction mixture in the cuvette.
Precision was shown to vary depending on whether the
reagents were mixed after the addition of each reagent;
sequential mixing, or after all reagents had been added;
terminal mixing (Fig.2.1). The slope of the line through
the phosphate standards was not significantly different
between the two protocols but the intercept decreased from
0.085 to 0.013 absorbance units and the precision at each
point was improved. The mean coefficient of variation
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FIGURE 2.1 Phosphate standard curves showing the
improvement in precision when reagents were sequentially
mixed.
• • Dose response of sequentially mixed standards
o © Dose response of terminally mixed standards
A—— A Precision profile of sequentially mixed
standards
A A Precision profile of terminally mixed
standards
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18.2% in terminally mixed assays. The decrease in
intercept of the sequentially mixed standard curve could
simply be a consequence of the improved precision or may be
due to the formation of a phosphate-independent complex in
the terminally mixed assay.
It was observed that, if addition of arsenite-citrate
reagent was delayed, a phosphate-independent complex was
formed which absorbed at 700nm. There was a significant
increase in the A7qq at 2.5min in the terminally mixed
assays but no significant increase in the sequentially
mixed assays until 7.5min (Table 2.1). In practice the
delay before addition of arsenite-citrate reagent was never
more than 5min and reagents were sequentially mixed.
By improving the precision of the phosphate assay the
detection limit for ouabain in the Na+K+ATPase incubation
decreased from 5.6xl0~^mol/l to 2xl0~^mol/l (Fig.2.2).
The detection limit is defined as the concentration of
ouabain which will depress phosphate production by two
standard deviations of the mean of the basal (uninhibited)
value.
The interassay CV of the phosphate assay was 2.8% as
determined by measurement of a 44nmol/l standard on 10,
different days over a period of 6 weeks (Table 2.2).
Results obtained from the assay of a 0.2jjmol/l and lpmol/1
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TABLE 2.1
INCREASES IN ABSORBANCE AS A FUNCTION OF DELAYED ADDITION
OF ARSENITE-CITRATE REAGENT IN SEQUENTIALLY AND TERMINALLY
MIXED PHOSPHATE ASSAYS





























* p<0.05 with respect to time zero value
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FIGURE 2.2 Dose-response curve for ouabain using
colorimetric Na+K+ATPase assay showing improved precision
when phosphate assay reagents were sequentially mixed.
ATPase incubation conditions: 75U/1, lh incubation,. 37°C.
• • Standard dose responses (sequential mixing)
o- o Standard dose responses (terminal mixing)
A A Precision profile (sequential mixing)
A .....A Precision profile (terminal mixing)
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TABLE 2.2
INTER-ASSAY PRECISION OF THE COLORIMETRIC METHOD FOR
MEASUREMENT OF PHOSPHATE
Measurement of a 44jjmol/l phosphate standard
on 10 different assays over a period of 6 weeks.












Standard deviation = 0.024
Coefficient of Variation = 2.8%
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ouabain standard in 6 consecutive assays were used to
estimate the combined precision of the Na+K+ATPase
incubation and phosphate assay (Table 2.3). A mean inter-
assay CV of 8% was obtained.
(b) Enzyme-linked Na+K+ATPase assay of Cobas FARA
centrifugal analyser.
An enzyme-linked Na+K+ATPase assay method (Hamlyn, et al,
(1982) was adapted for use on a Cobas FARA centrifugal
analyser. In this assay, hydrolysis of ATP is linked to
the oxidation of NADH by pyruvate kinase and lactate
dehydrogenase (Fig.2.3) and the reaction monitored by the
decrease in absorbance at 340nm. The enzyme activity can
be calculated by multiplying the rate of change in
absorbance by a factor which is derived from the Beer-
Lambert Law as shown in Figure 2.4. On the Cobas FARA the
light beam passes horizontally (i.e. radially) through the
cuvette so the light path is a function of the total volume
of liquid present in the cuvette. It can be deduced from
the calculations in Figure 2.4, that the total reaction
volume can be changed without altering the calculation
factor, as long as the sample volume remains the same,
because the radial light path (d) cancels out of the
calculation.
The complete program for the Cobas FARA is shown in Figure 2.5.
51
TABLE 2.3
COMBINED PRECISION OF THE Na+K+ATPase INCUBATION AND THE
COLORIMETRIC PHOSPHATE ASSAY
Results obtained for two ouabain standards in 6
consecutive assays.































Reaction scheme of enzyme-linked assay used on Cobas FARA
centrifugal analyser. Assay method based on that of
Hamlyn, et al, 1982.
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FIGURE 2.4 DERIVATION OF CALCULATION FACTOR FOR COBAS
FARA Na+K+ATPase ASSAY FROM BEER-LAMBERT LAW
Cobas cuvette dimensions = r x r x d
AA = change in absorbance at 340nm
c = concentration
1 = light path
£ = absorption coefficient of NADH
SV = sample volume









1 = d cm
AA = Eel












Dilute sample: SV/TV . . multiply by TV/SV
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6 2
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Briefly, 20jj1 of sample or ouabain standard, plus 40pl of
diluent (H2O), and 150pl FARA assay reagent (Appendix II)
were pipetted, mixed by centrifugation and pre-incubated
for 20s at 37°C. 20pl of Na+K+ATPase (dog kidney, Sigma;
500U/1) and 20^1 diluent were then pipetted, mixed and
incubated for 200s at 37°C. During the incubation 40
absorbance readings were taken, one every 5 seconds after
an initial reading at 0.5 seconds.
Enzyme activity was calculated over the period 60-200s
using the "kinsearch" calculation mode. In this mode, the
program will "search" for the linear part of the reaction
by drawing lines to each data point from a point equal in
absorbance to but 5s prior to the first absorbance
measurement. Beginning with the last data point, the
tangent of the angle formed between the line and the
horizontal is calculated. When the tangent is less than or
equal to the previous tangent the data point from which the
line has been drawn is taken as the end of the linear
range. The beginning of the linear range is defined in
the same way, by drawing lines from a point 5s prior to the
last data point but equal in absorbance and calculating the
tangent of the angle with the horizontal. The change in
absorbance per minute is calculated by linear regression
analysis of the points between the beginning and the end of
the linear range. If there are fewer than four data
points within the linear range, the program will not
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perform the calculation procedure on the data points and
will "flag" the sample "NON-LINEAR". The program also
checks the scatter of the data points within the linear
range. If one or more points lies outside the allowed
limit of +/-0.005 absorbance units the progam performs the
calculation on the data points but prints "NOISE" next to
the value on the results.
Inhibition caused by a sample was converted to ouabain
equivalents by comparison with a graph of percentage
inhibition of Na+K+ATPase versus ouabain concentration,
i.e. a ouabain standard dose-response curve. The
concentration range of the ouabain standards was 0.25-
1000^imol/l.
As shown in Figure 2.6, the absorbance change in the
presence of different standards has a wide range. A
compromise had to be reached where the zero standard i.e.
no inhibitor present, did not use all the NADH but where
the ouabain standards in the middle of the curve gave a
linear result. The time window chosen for calculating
activity was 60-200s.
The assay performed well with an intra-assay CV of no
greater than 2% and an inter-assay CV with a mean of 4.5%.
The inter-assay CV over 6 consecutive assays shows a
transient rise at 250pmol/l (Fig.2.7) which is due to the
(MESAIN
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FIGURE 2.6 Enzyme-linked Na+K+ATPase assay on Cobas
FARA. Change in absorbance at 340nm in the presence of
different ouabain standards.






FIGURE 2.7 Typical dose-response curve for ouabain using
the enzyme-linked Na+K+ATPase assay,
o o Standard dose responses
x x Precision profile - interassay CV over six
consecutive assays.
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decrease in the slope of the dose-response curve at that
point without a concomitant fall in the variation of the
response. At ouabain concentrations greater than
250pmol/l the variation in response was much less because
the concentration of ouabain was approaching that which
causes maximal inhibition of the enzyme and the curve
approached an asymptote.
4. MEASUREMENT OF DIGOXIN-LIKE ACTIVITY
Endogenous cardiac glycoside-like substances were expected
to be sufficiently similar to digoxin in structure that
they would be capable of cross-reacting with digoxin
antibodies. Eluates were investigated for cross-
reactivity with several digoxin radioimmunoassays; the
department of Clinical Chemistry "in-house" assay which is
used for routine measurement of patient samples and two
commercial kits.
(a) Commercial Digoxin Radioimmunoassay Kits
The kits were used as directed by the manufacturer's
instructions. Each kit used a different method to
IOC
separate the antibody-bound [I]-digoxin from the free
[ -j -digoxin.
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(i) Gammacoat™ [^^1 ]-Digoxin Radioimmunoassay Kit
(Clinical Assays, Massachusetts, U.S.A.)
The tubes used in this assay were pre-coated with anti-
IP K
digoxin antibody so separation of bound from free [ I]—
digoxin was achieved by simply decanting the liquid, which
contained the free digoxin, from the tubes.
[125i]-digoxin was diluted with phosphate buffered saline
(supplied with the kit), to give a 1.48kBq/100ml solution.
IOC
50jj1 of sample and 1ml of [ ^1]-digoxin solution were
pipetted into each tube. After a one hour incubation at
37°C the liquid was decanted and the tubes counted on a
gamma counter.
(ii) RIANEN™ [-^^1 ]-Digoxin Radioimmunoassay Kit
(New England Nuclear, Massachusetts, U.S.A.)
A prereacted first and second antibody complex is used to
1 p c , , 1 ? S
separate antibody-bound [ JI]-digoxin from free [XXsJI]~
digoxin.
IPS., . , .
[iiJi]-digoxin was supplied as a dilute solution in acetate
buffer (1.6kBq/ml). lOOpl sample, 500pl [^^1 ]-digoxin
solution and 500pl antibody complex were incubated at room
temperature. After 30 minutes, the tubes were centrifuged




The immunological reagents required for this assay were
supplied by the Scottish Antibody Production Unit (SAPU).
[l25i]-digoxin was obtained initially from CMD (UK) Ltd
(Bournemouth, U.K.) and latterly from Ciba Corning
Diagnostics Ltd (Hal'stead, Essex, U.K.). This was diluted
with phosphate buffer (pH 7.2; appendix II) to a
concentration of approximately lkBq/ml. Separation of
IOC
, .
bound [iiJI]-digoxin was achieved using a pre-precipitated
antibody suspension (Appendix II) which must be stirred
continuously during dispensing. Samples and reagents were
pipetted with a Dilutrend diluter (Clinicon Mannheim GMBH) .
1 OC
50jal sample, 400jul [X^-Ji] -digoxin solution and 400jil pre-
precipitated antibody complex were incubated for 30
minutes. The tubes were then centrifuged (1000 x g; 20
min; 4°C) and the supernatant decanted leaving a pellet of
IOC
antibody-bound [ I]-digoxin.
(c) Effect of sample diluent on "in-house" method
The results from the digoxin RIA were shown to be affected
by the sample matrix, a widely observed occurrence in
radioimmunoassays for steroids. Samples were to be
reconstituted in ammonium acetate but digoxin standards
diluted in ammonium acetate produced a curve which was
parallel to the serum standard curve but displaced to the
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right (Fig.2.8). Bovine serum albumin (BSA) was added to
each assay to increase the protein concentration to the
level obtained when a serum sample is added. This
produced a curve which was parallel to the buffer curve but
did not return the curve to the same position as the serum
curve (Fig.2 . 9) .
Although digoxin standards diluted in ammonium acetate
produced curves which had acceptable within batch variation
the between batch variation was less acceptable (Fig.2.8)
and the ammonium acetate control which was read from the
curves had a CV of 67% (Table 2.4).
The buffer used in the enzyme-linked Na+K+ATPase assay;
Tris-TES-salts (TTS), was also a possible candidate for
reconstitution of samples, digoxin standards were prepared
using TTS as the diluent. As with ammonium acetate, the
precision within a batch was adequate but between batches
the CV was greater than 10% for digoxin concentrations
above lnmol/1 (Fig.2.8). Controls prepared in TTS had
CV's greater than 10% (Fig.2.9).
When standards were diluted in digoxin RIA buffer a curve
was obtained which was very similar to the serum curve.
Precision was as good as the serum curve (Fig.2.8) and the
controls had acceptable CV's (Table 2.4). Unlike the



















FIGURE 2.8 Dose-response curves for digoxin RIA using
different diluents.
Mean and standard deviation of response at








FIGURE 2.9 Effect of addition of BSA to assay tubes
containing standards diluted in ammonium acetate.
1 Mean and standard deviation of response (no
additional BSA)















10 5.8 3.9 67
TTS 10 2.4 0.48 20
3.5 0.45 13
6.3 0.82 13
RIA Buffer 10 0.6 0.09 15
3.7 0.31 8
6.8 0.43 6
Serum 10 2.4 0.13 5
5.1 0.5 10
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was not displaced relative to the serum curve. Therefore,
digoxin standards were prepared using RIA buffer as the
diluent.
5. EXTRACTION AND SEPARATION METHODS
(a) Extraction using Sep-Pak C-^g Cartridges
(i) Method
Waters Sep-Pak octadecylsilane (C-^g) cartridges are
intended for sample preparation prior to further liquid
chromatography. The cartridges are first primed with a
solvent less polar than water, then washed with water prior
to addition of the sample. This is followed by a water
wash to flush out inorganic ions and then by a solvent or
series of solvents which become increasingly non-polar.
Compounds elute in order of decreasing polarity.
Sep-Pak cartridges were used to concentrate the methanol-
soluble fraction from human plasma, human serum, bovine
serum and bovine adrenal cortex cytosol. A similar
protocol was used for each sample. Liquids were pushed
through the cartridges using either nylon syringes under
hand pressure or using a Sep-Pak cartridge rack (Millipore
U.K., Harrow, Middlesex, U.K.) linked to a vacuum pump.
Each cartridge was primed with 5ml of methanol followed by
5ml of distilled water before the sample was applied. The
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fraction of the sample which did not bind to the
octadecylsilane was described as non-adsorbed filtrate
(NAF). After sample application the cartridge was rinsed
with 5-10ml of distilled water followed by 3-5ml of
methanol. Substances which eluted with methanol were
called eluate. Eluates were either collected into Pyrex
conical tubes (13ml) or collected into 5ml glass tubes and
transferred to polypropylene tubes (5ml) depending on which
drying apparatus was to be used.
Initially, eluates were dried down using a water bath to
heat the tubes and a manifold of plastic tubes joined by
rubber and plastic tubing to a compressor or a nitrogen
cylinder to blow air into them. More recently, a Techne
sample concentrator (Techne (Cambridge) Ltd., Cambridge,
U.K.) was purchased which performed the same task in a more
sophisticated manner (Fig.2.10). The eluates were dried
down at 37°C or 50°C.
When it was necessary to achieve a greater degree of
concentration than could be obtained by a single
extraction, the eluate was extracted on a second cartridge.
The eluate from the repeat extraction was termed
concentrated eluate.
(ii) Recovery Experiments
Ouabain was used as a model in experiments to investigate
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FIGURE 2.10
APPARATUS USED TO DRY DOWN SEP-PAK ELUATES
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the recovery of inhibitory substances using this extraction
method. When the enzyme-linked Na+K+ATPase assay was
introduced the performance of the method was re-evaluated.
Initially recovery was assessed using the colorimetric
Na+K+ATPase assay. The methanolic eluate was collected
into conical 13ml Pyrex tubes and dried down under air, in
a water bath at 50°C. The main problem with this method
was the small number of positions available on the drying
apparatus which limited the number of samples which could
be extracted, dried and assayed on any one day.
The effect of the methanol elution volume on recovery was
investigated by loading cartridges with 5ml of lpmol/1
ouabain in NAF. The NAF was used because it was a serum¬
like matrix which should not contain any endogenous
Na+K+ATPase inhibitor. The cartridges were eluted with 1-
10ml of methanol. The recovery varied between 70 and 120%
for elutions volumes up to 5ml but was less than 70% for
volumes greater than 5ml (Fig.2.11). Recoveries greater
than 100% were due to variation in the assay resulting in
the measurement of slightly more ouabain than was added.
The lower recoveries for elution volumes of 6ml and 10ml
may be due to losses on the side of the tubes. An elution
volume of 5ml was chosen to give the maximum possible
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FIGURE 2.11 Sep-Pak extraction method - effect of
methanol elution volume on recovery of ouabain. Ouabain
added = ljjmol/1.
Mean and standard deviation of triplicate
incubation (colorimetric Na+K+ATPase assay)
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Recovery did not appear to be affected by sample volume.
In an experiment where the loading volume was 2.5, 5, or
10ml the recovery was not related to loading volume (Table
2.5). This experiment also confirmed that ouabain was
only detected in the eluate and not in the NAF or in the
water wash.
The use of a Techne sample concentrator and the development
of the enzyme-linked Na+K+ATPase assay on the Cobas FARA
made it necessary to repeat the recovery experiments
because the eluate was dried down in different tubes and a
different Na+K+ATPase assay was being used.
Recovery experiments were performed using ouabain diluted
in NAF as a model. In all cases the cartridges were
primed with 5ml methanol followed by 5ml water and rinsed
with 5ml water prior to elution with methanol.
The maximum volume of the tubes for the drying apparatus
was 5ml. The effect of varying the methanol elution
volume was investigated and it was observed that recovery




SEP-PAK EXTRACTION METHOD: EFFECT OF SAMPLE VOLUME ON
RECOVERY
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FIGURE 2.12 Sep-Pak extraction method - effect of
methanol elution volume on recovery of ouabain. Ouabain
added = lOOnmoles.
I f Mean and standard deviation of duplicate
extraction, single estimation of ouabain
concentration (enzyme-linked Na+K+ATPase ass
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Recovery was not affected by varying the sample volume
(Fig.2.13) although the values were greater than 100%
throughout the range. The recoveries greater than 100%
may have been due to the use of NAF as a diluent. It is
possible that not all of the inhibitory factor had been
removed from the NAF and so the inhibition measured would
have been due to the ouabain which had been added and any
remaining factor present in the NAF.
Comparable recoveries were observed for reconstitution
volumes of 200pl to 1ml (Fig.2.14). A reconstitution
volume of lOOjul had a recovery which was greater than 100%
which may have been due to the presence of an inhibitory
factor in the NAF, as discussed above'.
(b) Separation using reverse-phase high performance liquid
chromatography
Concentrated eluates were separated into several active
fractions using reverse-phase high performance liquid
chromatography (HPLC) . The HPLC system was obtained from
Waters (Instruments) Ltd. (Northwich, Cheshire) and
comprised a Waters Model 680 automated gradient controller,
two Waters Model 510 pumps, a Model 441 absorbance detector
and a Model U6K sample injector. The detector and
controller were connected to a BBC SE120 pen recorder (BBC
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FIGURE 2.13 Sep-Pak extraction method - effect of sample
volume on recovery of ouabain. Ouabain added = 50nmoles.
Mean and standard deviation of duplicate
extraction, single estimate of ouabain
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FIGURE 2.14 Sep-Pak extraction method - effect of
reconstitution volume on recovery of ouabain. Ouabain
added = lOnmoles.
5 1 Mean and standard deviation of duplicate
extraction, single estimate of ouabain
concentration (enzyme-linked Na+K+ATPase assay)
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were filtered before use using Waters filtration apparatus
and 0.5^im filters.
After samples had been microfuged to remove particulate
matter, they were applied to a Waters pBondapak
octadecylsilane column (3.9mm x 30cm; Waters Associates,
Harrow, Middlesex) and eluted with a 20-100% acetonitrile
gradient at a flow rate of lml/min. 1ml fractions were
collected with a LKB Superrac 2211 fraction collector (LKB,
Bromma, Sweden) and dried down under air at 37°C using the
Techne sample concentrator. Fractions were reconstituted
in 250^1 20mM ammonium acetate (pH 7.4; Appendix II) and
assayed for the ability to inhibit Na+K+ATPase and to
cross-react with digoxin antibodies.
6. PREPARATION OF ISOLATED ADRENAL CELLS AND THEIR
INCUBATION WITH AGONISTS
(a) Preparation of isolated cells
Adrenal cells were prepared from bovine adrenal glands
using a method similar to that of Crivello, et al, (1982).
Bovine adrenal glands were collected from the abattoir and
transported to the laboratory in ice-cold 0.155M saline
where the fat was initially quickly trimmed and then
carefully dissected from the glands. The glands were kept
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moist, with saline or Earle's balanced salt solution (EBS;
NBL Ltd., Cramlington, Northumberland, U.K.), throughout
this procedure. 0.2%BSA and 0.1%glucose were added to EBS
and medium 199 (M199; Flow Laboratories, Rickmansworth,
Herts., U.K.) which brought the total glucose concentration
to 0.2%. Slices were taken from the outside of the glands
using a Staddie-Rigg microtome; the first slice was
considered to contain predominantly glomerulosa cells, the
second slice predominantly fasciculata cells. Cells were
prepared in parallel from these two types of sliqe. The
slices were chopped into extremely small pieces and
incubated in 2%BSA-EBS containing 1.5mg/ml collagenase for
lhr. The mixture was dispersed every 20min using a 5ml
"finnpipette" with a tip with a cut end. Digested
material was passed through 100pm nylon gauze, centrifuged
(100 x g, 15min, 20°C), and the pellet resuspended in
medium 199. This washing procedure was repeated a further
three times. After the centrifuging for the fourth time
the resuspended pellet was passed through a 20pm nylon
gauze and the cell suspension diluted to the required
volume.
Cells were counted using a cytometer. The number of cells
in a 4x4 grid multiplied by 1x10^ was equivalent to the
number of cells per ml of suspension. Cells were counted
routinely and the average value of the number of cells
present in each of the four 4x4 grids was calculated.
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(b) Incubation of isolated adrenal cells with agonists
The isolated adrenal cells were tested for their
steroidogenic response to All, ACTH, and to the active
fractions from the HPLC separation of adrenal cortex
cytosol eluate.
Cell suspension (225pl) was incubated for lhr at 37°C in
the presence of 25pl agonist and 250pl M199 in a shaking
waterbath. The incubate was centrifuged (200 x g, 15min,
4°C) and the supernatant decanted into fresh tubes (3ml)
and stored at -20°C prior to measurement of steroid
concentration by radioimmunoassay.
7. RADIOIMMUNOASSAY OF ADRENAL STEROIDS
Like the cells of the human adrenal gland, bovine
glomerulosa cells produce predominantly aldosterone and
fasciculata cells produce predominantly Cortisol; both
types of cell produce corticosterone. In order to assess
whether the active fractions from HPLC had a differential
effect on the steroid production in both types of cell the
concentration of aldosterone, corticosterone and Cortisol
in the supernatants from the cell incubations was measured
using appropriate radioimmunoassays. Assays were pipetted
using the same automatic diluter used for the digoxin
radioimmunoassay and all standards were diluted in 0.2%BSA-EBS.
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(a) Cortisol Radioimmunoassay
Cortisol concentrations were measured using an "in-house"
Cortisol radioimmunoassay which uses immunological reagents
i o K
provided by SAPU. In this method, [ JI]-Cortisol
(Amersham International pic, Amersham, Bucks., U.K.) was
diluted with 0.1M citrate buffer (pH 4; Appendix II) to a
concentration of 330Bq/ml.
i o c
25jul of sample and 400^1 of [ I]-Cortisol followed by
250jul of pre-precipitated Cortisol antibody (Appendix II)
were pipetted into assay tubes and incubated at 37°C.
After 70 minutes the tubes were centrifuged (3000 x g;
30min) and the supernatant decanted. Cortisol standards
were prepared from lOmM Cortisol st-ock, in ethanol, by
dilution in EBS containing 0.2%BSA and stored at -20°C.
The standards covered the range 25-2000nmol/l.
The Cortisol concentrations in some of the cell
preparations were quite low so the assay was sensitised by
increasing the sample volume to lOO^ul and diluting the pre-
precipitated antibody two fold. An alternative set of
standards were prepared for use with this more sensitive
assay. These standards covered the range l-2000nmol/l.
Typical dose-response curves for the two assays are shown
in Figures 2.15 and 2.16.
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FIGURE 2.15 Typical dose-reponse curve and precision
profile for the "in-house" method Cortisol RIA, as
calculated by the WHO immunoassay program.
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FIGURE 2.16 Typical dose-response curve and precision
profile for the sensitive Cortisol RIA, as calculated by
the WHO immunoassay program.
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The inter-assay CV of the assays was assessed from values
obtained for controls in several different batches (Table
2.6). The "in-house" method produces results with
acceptable CV i.e. less than 10%, for Cortisol
concentrations 100-2000nmol/l. The sensitive assay was
acceptable from 14-800nmol/l.
(b) Corticosterone Radioimmunoassay
Corticosterone antiserum and corticosterone stock in
ethanol (approx. 3mmol/l) were kindly provided by Dr. B.C.
Williams, Department of Medicine, Western General Hospital,
Edinburgh. Corticosterone standards were prepared which
covered the range 0.5-200nmol/l and were stored at -20°C.
12 5
[I]-corticosterone was obtained from Immunodiagnostics
Ltd. (Washington, Tyne & Wear).
The assay was performed essentially according to the method
of Al-Dujaili, et al, (1981). In this assay a "pre-mix"
was prepared which contained antibody (1:50 000) and
IOC
[I]-corticosterone (427Bq/ml) diluted in 50mM phosphate
buffer (pH 7.4; Appendix II). Sample (25jul) and "pre-mix"
(200pl) were incubated overnight at 4°C. Following
incubation, 500^1 of charcoal suspension (Appendix II) were
added to each tube and, after vortexing, the tubes were
centrifuged (1700 x g; 30 min) and the supernatant
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TABLE 2.6










In-house method 5 212 18 8
5 393 36 9
5 773 43 5
Sensitive method 4 13 3 23
4 80 9 11
4 636 • 91 7
CORTICOSTERONE 8 1.1 0.1 9
8 7.2 0.1 10
8 82 17 21
ALDOSTERONE 8 0.59 0.07 12
8 8.7 1.1 13
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1 o c
decanted. In this method it is the free [ I]—
corticosterone which is bound to the charcoal and counted.
Figure 2.17 shows a typical dose-response curve and
precision profile for the corticosterone assay. The
precision in the corticosterone assay was not as good as
that in the Cortisol assays. The assay was most reliable
in the range l.l-46nmol/l. The inter-assay CV (see Table
2.6) was approximately 10% which indicates that the
precision between assays was better than that within
assays.
(c) Aldosterone Radioimmunoassay
Antiserum against aldosterone was provided by Dr. B.C.
Williams. Aldosterone stock solution in ethanol was
freshly prepared from crystalline aldosterone obtained from
Sigma Chemical Co. Ltd. (Poole, Dorset). Standards were
prepared from this stock (approx. 3mM) by dilution in
0.2%BSA-EBS and covered the range 0.05-20nmol/l. These
standards and the ethanol stock solution were stored at
-20°C. [125ij-aldosterone was supplied by
Immunodiagnostics Ltd. (Washington, Tyne & Wear).
The aldosterone assay method was based on that of Al-
Dujaili and Edwards (1978). The method for the
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FIGURE 2.17 Typical dose-response curve and precision
profile for the corticosterone RIA, as calculated by the
WHO immunoassay program.
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corticosterone assay except that the antibody was used at a
1 OC
1:100 000 dilution and the [I]-aldosterone concentration
was 444Bq/ml.
A typical dose-response curve and precision profile is
shown in Figure 2.18. As with the corticosterone assay,
the inter-assay CV (Table 2.6) was slightly better than the
intra-assay CV.
8. MEASUREMENT OF NON-ESTERIFIED FATTY ACIDS USING THE
COBAS BIO
Non-esterified fatty acids (NEFA) were measured using a
colorimetric kit method (Wako NEFA C test kit) which had
been adapted for use on a Cobas Bio centrifugal analyser
following the procedure of Knox and Jones (1984). The
Cobas Bio analyser is a less sophisticated version of the
Cobas FARA. The Cobas FARA has more complicated but
flexible software than the Cobas Bio but the optical and
measurement systems are identical. The NEFA assay was an
enzyme-linked method which produced a coloured end point.
The absorbance was read at 550nm and NEFA concentrations in
samples were calculated by comparison with known
concentrations of standards. In this method the standards
were dilutions of oleic acid, however, the kit is not
specific for oleic acid nor is it intended to be.
According to recovery results quoted in the manufacturer's
95








FIGURE 2.18 Typical dose-response curve and precision
profile for the aldosterone RIA, as calculated by the WHO
immunoassay program.
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instruction leaflet, the kit can detect both saturated and
unsaturated NEFA's containing 6 to 22 carbon atoms.
9. GAMMA COUNTING
The radioimmunoassays were counted using an NE1600 gamma
counter (Nuclear Enterprises, Reading, U.K.) linked to an
Apple II computer. Standard curves were calculated from
the raw counts using the WHO Immunoassay program (Version
5.3). This program was also used to interpolate values
for the samples from the curves and to provide precision
profiles for the assays.
10. TRYPTIC DIGESTION
Fractions from HPLC which showed both inhibitory activity
and cross-reactivity with digoxin antibodies were pooled
and subjected to tryptic digestion. Pooled fractions
(200pl) were incubated with 20jul of trypsin (lg/1 final
concentration) at 37°C. The incubation was stopped after
four hours by adding 20pl soya bean trypsin inhibitor (lg/1
final concentration). The HPLC fractions were
reconstituted in ammonium acetate (20mM, pH7.4), so
controls for the tryptic digestion contained 200pl of this
buffer in place of the fractions. After tryptic
digestion, the samples and controls were measured for the
ability to inhibit Na+K+ATPase in the enzyme-linked assay
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on the Cobas FARA centrifugal analyser. Pooled fractions
which had not been subjected to tryptic digestion were also
assayed simultaneously with the samples and controls.





1. MEASUREMENT OF Na+K+ATPase INHIBITION AND DIGOXIN
CROSS-REACTIVITY IN EXTRACTS OF HUMAN PLASMA
Plasma samples from normotensive and hypertensive subjects
were stored at -20°C until required for assay. They were
then thawed and extracted using Sep-Pak Cq cartridges. A
new cartridge was used for each sample. Eluates were
compared using both the colorimetric Na+K+ATPase assay and
the Cobas FARA Na+K+ATPase assay.
(a) Colorimetric Na~l~K+ATPase Assay
(i) Pilot study
A pilot study was organised to assess whether measurable
Na+K+ATPase inhibition could be extracted from the volume
of plasma usually obtained from an individual patient.
Plasma collected from 12 normotensive and 12 hypertensive
patients was used for this study.
Eluates were dried down under air in a water bath at 50°C,
reconstituted in non-adsorbed filtrate (350^1 NAF) and
stored at -20°C until assayed. The enzyme concentration
in the Na+K+ATPase assay was 75U/1 and the incubation time
was 60min. Samples were assayed in triplicate with their
own triplicate control for non-enzymic hydrolysis of ATP.
In this control the incubation mixture was identical but
the enzyme was added after the 1ml of 10% TCA.
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Incubation mixtures which contained eluate produced
significantly less phosphate than those containing NAF
(Table 3.1). This indicated that it was possible to
extract and concentrate inhibitory substances from the
volume of plasma routinely obtained from a single patient.
There was no significant difference between normotensives
and hypertensives as assessed by a student's T-Test.
This pilot study highlighted a problem associated with
reconstituting the eluate in NAF. The A7qq values for the
eluate were greater than those of the incubation control.
Since the incubation control contained buffer in place of
sample, this result indicated that a substance or
substances present in NAF were interfering with the assay
in some way. For this reason NAF was included in the
reaction mixtures of the incubation control and the ouabain
standards during the subsequent large study of samples from
normotensive and hypertensive patients.
(ii) Large study
The large study comprised plasma samples from 32
normotensives and from 46 hypertensives. The range of
ages and mean arterial blood pressures (MAP: diastolic +
1/3 pulse pressure) for normotensives and hypertensives




INHIBITION OF Na+K+ATPase BY SEP-PAK ELUATES














* p<0.05 with respect to NAF (Paired T-Test)
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In this study the drying time was reduced by decreasing the
methanol elution volume to 3ml. Eluates were
reconstituted in 500pl of NAF, divided into 7 portions; 6
x 50pl, 1 x 20Ctyul, and stored at -20°C. The 50pl portions
were used in the Na+K+ATPase assay and the 200jul of eluate
were retained for measurement of cross-reactivity in a
digoxin RIA.
In contrast with the results in the pilot study, no
significant difference was observed between the A-yQQ of the
incubations containing eluate and those containing NAF.
This could have been due to the different reconstitution
volumes used in the two assays; 350^1 in the pilot study
and 500pl in the larger study. A larger volume of eluate
was required- for the second study because eluates were
assayed for cross-reactivity with digoxin antibodies as
well as inhibitory capacity. This meant that the eluates
in the large study were not concentrated to the same extent
as those in the pilot study and so the concentration of the
inhibitory substance may not have been high enough to be
measurable with this assay. Another possibility was that
the substances present in the NAF which increase the A-^qq
of the incubation mixture may have masked the small amount
of inhibition that was present.
The cross-reactivity of the eluates and NAF with digoxin
antibodies was measured using a digoxin RIA kit obtained
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from NEN, Massachusetts, U.S.A.. No significant
difference was noted between the eluates from normotensive
and hypertensive plasma and no correlation was observed
between MAP and digoxin equivalent of the eluate.
(b) Enzyme-linked Na"t"K+ATPase Assay on Cobas FARA
The inhibitory capacity of eluates prepared from the plasma
of a large number of normotensives and hypertensives was
measured using the enzyme-linked Na+K+ATPase assay.
Samples from many of the individuals in this study had also
been assessed in the large study with the colorimetric
Na+K+ATPase assay. 34 normotensives, age 27-57yrs, MAP 88-
107mmHg, and 50 hypertensives, age 21-67yrs, MAP 113-
173mmHg, were studied.
Some changes were made to the extraction protocol for this
study. The Sep-Pak C18 extraction procedure was altered
by increasing the amount of distilled water used to wash
the cartridge to 10ml to ensure that all inorganic salts
were being washed out of the cartridge before the sample
was eluted. The drying temperature was also reduced to
37°C to prevent any possible loss of activity due to
incubation at 50°C. Eluates were reconstituted in 170pl
digoxin RIA buffer which eliminated the problems associated
with reconstitution in NAF and made it possible to obtain
quantitatively reliable results from the digoxin RIA.
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Samples were thawed, extracted and assayed on the same day.
In all samples the NAF and the water wash were devoid of
inhibitory activity. Inhibition due to eluates was
converted to ouabain equivalents by interpolating values
from a ouabain standard dose-response curve. This ouabain
equivalent was then corrected for the concentration factor
to give ^imol/1 ouabain in the original plasma. Cross-
reactivity was quantified in digoxin equivalents which were
similarly corrected to give pmol/1 digoxin in the original
plasma.
The mean ouabain equivalents and mean digoxin equivalents
for the eluates prepared from the plasma of normotensive
and hypertensive patients are shown in Table 3.2. These
results were analysed using a Mann-Whitney U-test and there
was no significant difference between the two patient
groups. The dot diagrams in Figure 3.1 demonstrate the
considerable variation in results. Linear regression
analysis showed no correlation between MAP and ouabain
equivalents, between MAP and digoxin equivalent or between
ouabain equivalent and digoxin equivalent.
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TABLE 3.2
OUABAIN AND DIGOXIN EQUIVALENTS PRESENT IN ELUATES FROM
NORMOTENSIVE AND HYPERTENSIVE PLASMA
NORMOTENSIVE HYPERTENSIVE
SUBJECTS SUBJECTS
Concentration in original MEAN SD MEAN SD
plasma sample
Ouabain equivalent: jimol/1 0.61 0.31 0.59 0.78
Digoxin equivalent: pmol/1 42.9 8.2 42.5 15.9


































FIGURE 3.1 Activity extracted from plasma samples
obtained from normotensive and hypertensive subjects
expressed as ouabain and digoxin equivalents (concentration
in the original plasma sample). There was no correlation
between these two activities.
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2. MEASUREMENT OF Na+K+ATPase INHIBITION AND DIGOXIN
CROSS-REACTIVITY IN CONCENTRATED ELUATES
(a) Concentrated eluates prepared from human serum
Pooled normal plasma and pooled polycythaemic serum and
plasma were used to prepare sufficient eluate for dose-
response curves of Na+K+ATPase inhibition. Details of the
different concentrations achieved and the Na+K+ATPase assay
conditions are given in Table 3.3. Concentrated eluates
were reconstituted and diluted in NAF and assayed for the
ability to inhibit Na+K+ATPase. As shown in Figure 3.2,
only the concentrated eluate from the normotensive
volunteers produced inhibition. No inhibition was
observed with the concentrated eluate from the plasma of
polycythaemic patients despite achieving a concentration
factor which was twice that of the normotensive pool.
(b) Concentrated eluate prepared from bovine serum
Bovine serum was investigated as a potential source of
Na+K+ATPase inhibitor because it was available in very
large quantities from a local abattoir and could therefore
be concentrated to a greater extent than human serum.
Blood was collected into plastic vessels and serum
separated by centrifugation. Dilutions of concentrated
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TABLE 3.3
CONCENTRATED ELUATES: CONCENTRATION FACTOR ACHIEVED AND
COLORIMETRIC ASSAY CONDITIONS





volunteers 120 25 U/l 4 h
Pooled serum from
polycythaemic subjects 160 6.25 U/l 16 h
Hypertensive subject
with polycythaemia 344 25 U/l 4 h
%ATPqsg Activity 100- 90- 80-' 100- 90- 80^ . 100-1 90- 80-
2550100 ConcentrationFactor
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FIGURE 3.2 Dose-response curves of concentrated eluates.
Assay conditions are presented in table 3.3.
o o Eluate prepared from pooled plasma of
normotensive subjects
x x Eluate prepared from pooled serum of
polycythaemic subjects
• • Eluate prepared from plasma of a
polycythaemic subject who was also hypertensive
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eluate were tested for the ability to inhibit Na+K+ATPase
and to cross-react with digoxin antibodies.
When dilutions of concentrated eluate were measured in the
colorimetric Na+K+ATPase assay a curve was obtained with a
maximum inhibition of 62% for a 200-fold concentration of
serum (Fig.3.3) .
Concentrated eluate in NAF was stored for nine months at
-20°C. Once thawed it was divided into two aliquots; one
was re-extracted on a Sep-Pak C-^g cartridge and
reconstituted in tris-buffered saline (TBS), the other
aliquot remained in NAF. These eluates were diluted with
the appropriate diluent; either NAF or TBS, and assayed on
the enzyme-linked Na+K+ATPase assay on the Cobas Bio. The
enzyme concentration was 250U/1, 10s readings were taken
between 200s and 400s. Identical % inhibitions were
obtained for the dilution curves in NAF in the colorimetric
Na+K+ATPase assay and in the enzyme-linked assay but much
more inhibition for a given concentration factor was
obtained if the eluate was reconstituted in TBS (Fig.3.4).
On further investigation it was shown that NAF contained
approximately 20U/1 of ATPase-like activity of which 15U/1
was due to hydrolysis of ATP in the absence of Na+K+ATPase
and 5U/1 was due to ATP-independent oxidation of NADH.
This indicated that the ability to detect low
concentrations of inhibitor would be increased by




FIGURE 3.3 Dose-response curve of inhibition of
Na+K+ATPase activity by concentrated eluate prepared from
bovine serum measured using the colorimetric assay.
j 1 Mean and standard deviation of response
(triplicate incubation)





FIGURE 3.4 Dose-response curve of inhibition of
Na+K+ATPase activity by concentrated eluate prepared from
bovine serum measured using the enzyme-linked assay.
Comparison of different diluents which shows that NAF
contains substances which interfere in the assay and mask
the inhibition.
• • Diluent = NAF
o o Diluent = Tris-buffered saline
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reconstitution of eluates in buffer because there would
appear to be something present in NAF which interferes in
the Na+K+ATPase assay. This confirmed the earlier work
with the colorimetric assay where it was observed that the
presence of NAF in the incubation mixture resulted in a
higher production of phosphate.
Concentrated eluate from bovine serum was diluted in NAF
and the dilutions measured for the ability to cross-react
in three different digoxin RIA's. Two commercial kits
were used, a double antibody method from NEN and a coated
tube method from Clinical Assays. An "in-house" method
was also tested for cross-reactivity. This assay used
SAPU reagents and was a pre-precipitated double antibody
method. The bovine serum concentrated eluate cross-
reacted in all three assays but to different degrees
(Fig.3.5), probably because of variation in the affinity of
the antibodies from the different assays for the cross-
reactive substance(s). The NEN assay showed most cross-
reactivity, the Clinical Assays method was least sensitive
to the factor (s) in the eluate. The SAPU antibody showed
adequate cross-reactivity and was used more frequently than
the commercial assays for reasons of economy.
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FIGURE 3.5 Cross-reactivity of concentrated eluate,
prepared from bovine serum, in three different digoxin
radioimmunoassays.
o o "In-house" method using SAPU antibody
x x Digoxin RIA kit supplied by NEN
• • Digoxin RIA kit supplied by Clinical Assays
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3. SEPARATION OF ACTIVE FRACTIONS FROM BOVINE SERUM
CONCENTRATED ELUATE USING HPLC
A second concentrated eluate was prepared from another pool
of bovine serum and separated on high performance liquid
chromatography (HPLC). A jaBondapak C-^g column was
connected to a Waters gradient HPLC system and the sample
eluted with a 20-100% acetonitrile gradient. Fractions
were collected, dried down and reconstituted in ammonium
acetate (pH7.4, 20mM) and measured for the ability to
inhibit Na+K+ATPase and cross-react in a digoxin RIA.
Figure 3.6 shows the profile obtained when 1ml of eluate,
which represented a 600-fold concentration of serum, was
applied to the HPLC system. There were three peaks of
inhibition and three peaks of digoxin cross-reactivity.
Two peaks of inhibition co-eluted with two of the peaks of
digoxin cross-reactivity but the major peak of inhibition
did not cross-react with digoxin antibodies. The levels
of inhibition at the summit of each peak were not very
high. To achieve greater inhibition in each peak it would
be necessary to concentrate the bovine serum to a greater
extent. It was not possible to repeat this separation
because there was insufficent sample.














FIGURE 3.6 HPLC profile of concentrated eluate prepared
from bovine serum showing peaks of inhibitory activity and
digoxin cross-reactivity. Sample = 1ml of 600-fold-
concentrated eluate (relative to original serum
concentration).
• • % Inhibition of Na+K+ATPase
o o Cross-reactivity expressed as digoxin
equivalents
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4. EXTRACTION AND SEPARATION OF INHIBITION AND
CROSS-REACTIVITY FROM BOVINE ADRENAL CORTEX
It was reported that digoxin-like cross-reactivity was
present in the adrenal gland of the rabbit (Schreiber, et
al, 1981b) and the rat (Schreiber, et ad, 1981a; Valdes,
et al, 1985). Since it was possible to extract inhibitory
and cross-reactive substances from bovine serum, it was
considered likely that the bovine adrenal gland could also
be a source of these substances. Bovine adrenal cortex
cytosol was extracted using Sep-Pak C-^g cartridges and
tested for the ability to cross-react with digoxin
antibodies and inhibit Na+K+ATPase.
(a) Dilution curve of Sep-Pak eluate
Cytosol was prepared from bovine adrenal cortex and
extracted on a Sep-Pak C^g cartridge to produce an eluate
which was concentrated 200-fold, with respect to the
original cytosol, in one step. The cytosol was shown to
contain substances which were capable of inhibiting
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FIGURE 3.7 Dose-response curve of inhibition of
Na+K+ATPase and cross-reactivity with digoxin antibodies by
concentrated eluate prepared from adrenal cortex cytosol.
0 ~° Inhibitory activity
"• Cross-reactivity
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(b) Separation of active fractions from adrenal cortex
cytosol eluate using HPLC
Adrenal cortex cytosol was concentrated using Sep-Pak C-^g
cartridges and the eluate was reconstituted in 20%
acetonitrile to give a concentration factor of 200. The
eluate was microfuged to remove particulate matter,
injected onto a Waters jjBondapak C-j_g column and eluted with
a 20 to 100% acetonitrile gradient. 1ml fractions were
collected, reconstituted in 250pl ammonium acetate. (pH7.4,
20mM) and measured for the ability to inhibit Na+K+ATPase,
cross-react with digoxin antibodies, cross-react with
Cortisol antibodies and for the presence of non-esterified
fatty acids (NEFA) .
HPLC of bovine adrenal cortex cytosol produced several
peaks of Na+K+ATPase inhibition and several peaks of
digoxin cross-reactivity but inhibition and cross-
reactivity co-elute in only two positions (Fig.3.8).
Several peaks of Cortisol cross-reactivity were also
obtained which co-eluted with those peaks which cross-
reacted with digoxin antibodies (Fig.3.9). The largest
peak of Cortisol cross-reactivity had a peak value of
approximately 0.8mmol/l and was probably due to native
Cortisol.
Digoxin Equivalent/nmol/l 4-0-io—° 3-0- 2-0- 1-0- 0J%ATPase Inhibition 60-i*—• 40- 20- 0J
i
0





FIGURE 3.8 HPLC profile of concentrated eluate prepared
from bovine adrenal cortex cytosol showing several peaks of
inhibitory activity and several peaks of cross-reactivity.
Sample = 1ml of 200-fold concentrated eluate (relative to
original cytosol concentration)
• « % Inhibition of Na+K+ATPase
o o Cross-reactivity expressed as digoxin
equivalents

























FIGURE 3.9 HPLC profile of concentrated eluate prepared
from bovine adrenal cortex cytosol showing elution position
of peaks of Cortisol cross-reactivity in relation to the
peaks of inhibitory activity and digoxin cross-reactivity.
Sample = 1ml of 200-fold concentrated eluate (relative to
original cytosol concentration)
•- • % Inhibition of Na+K+ATPase
° o Cross-reactivity with digoxin antibodies
expressed as digoxin equivalents
x x Cross-reactivity with Cortisol antibodies
expressed as umol/1 Cortisol
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NEFA was present in several fractions which eluted in four
peaks before and one peak after those of interest
(Fig.3.10). The last peak of NEFA co-eluted with a peak
of inhibition but showed no cross-reactivity with the
antibodies.
5. EFFECT OF ACTIVE FRACTIONS FROM HPLC OF BOVINE ADRENAL
CORTEX ON STEROIDOGENESIS IN ISOLATED ADRENAL CELLS
The fractions from HPLC of bovine adrenal cortex cytosol
which showed both inhibition and cross-reactivity were
combined and designated peak 1 and peak 2 (see Fig.3.8).
These peak fractions were tested on isolated adrenal cells
for their effect on steroidogenesis.
Peak 1 had no effect on Cortisol or corticosterone
production in both glomerulosa cells and fasciculata cells
but did stimulate aldosterone production in both cell types
by 20-41 fold in the glomerulosa cells and 17-20 fold in
the fasciculata cells.
The production of all three steroids was stimulated by peak
2. In glomerulosa cells there was a slight increase in
Cortisol production (as much as 2 fold) and a 17-20 and 20-
49 fold increase in corticosterone and aldosterone
production respectively. Cortisol production was
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FIGURE 3.10 HPLC profile of concentrated eluate prepared
from bovine adrenal cortex cytosol showing the elution
position of NEFA in relation to the peaks of inhibitory
activity and digoxin cross-reactivity. Sample = 1ml of
200-fold concentrated eluate (relative to original cytosol
concentration)
• • % Inhibition of Na+K+ATPase
o o Cross-reactivity with digoxin antibodies
expressed as digoxin equivalents
x x NEFA
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stimulated 12-17 fold, corticosterone 10 fold and
aldosterone 10-15 fold in fasciculata cells.
Where there was stimulation of steroid production it was
far in excess of the stimulation which was observed with
All or ACTH; which achieved a maximal stimulation of 6
fold (Table 3.4). This may indicate that the stimulation
due to the presence of the peak fractions arises because
they are in fact steroid precursors. It is also possible
that these are novel steroid stimulating compounds.
TABLE3.4 STIMULATIONOFBOVINEADRENALCO TEXE LSYANGIOTE SINI ,C HNDHP CFRACTIO FROMADRENALCO TEXYTOSO Stimulationofsteroidproductiexpresseaultipl sthb s lste oids cr ti nftc l . Resultsfromtwocellpreparations;A,B AGONIST ANGIOTENSINI :GLOMERULOSACEL CORTISOLORTICOSTER NEALDOS ERONE A B MEAN
FASCICULATACEL S




























It has been proposed (de Wardener, 1982) that essential
hypertension develops as a result of a circulating
natriuretic hormone which has its effect through the
inhibition of Na+K+ATPase. Since cardiac glycosides are
naturally occurring ligands for Na+K+ATPase, the
natriuretic hormone has been sought on the basis that it
may have similar properties and possibly structural
similarities to the cardiac glycosides. Methods employed
in the search for an endogenous cardiac glycoside-like
substance have included measurement of ability to inhibit
Na+K+ATPase, competition with [^H]-ouabain for binding
sites on Na+K+ATPase and cross-reactivity with digoxin
antibodies or antibodies to other cardiac glycosides.
In this thesis, fractions extracted from plasma and cytosol
were investigated for the possession of two of these
properties; inhibition of Na+K+ATPase and cross-reactivity
with digoxin antibodies. It was necessary to develop
methods for measuring Na+K+ATPase and, although a
sufficiently sensitive RIA for digoxin was in routine use
in the Clinical Chemistry department, it was adapted for
use with a non-serum matrix. An extraction procedure was
developed and tested for its ability to extract cardiac
glycoside-like activity from serum or plasma and from
adrenal cortex cytosol. Extracts from adrenal cortex were
tested for their effect on steroidogenesis in isolated
cells.
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1. PERFORMANCE OF METHODS
(a) Assays of cardiac glycoside-like activity
Different workers have used a variety of methods to measure
the inhibition of Na+K+ATPase by serum or tissue extracts.
The most direct assays of enzyme activity comprise an
incubation followed by measurement of the phosphate
released by the action of the enzyme on ATP. Several
methods have been used to quantify the phosphate released;
a colorimetric method (Gruber, et al, 1980), measurement of
the "^P released from [^P]-ATP (Cloix, et al, 1983) and by
an enzyme-linked method where the amount of phosphate
produced by the Na+K+ATPase was quantified by the decrease
in absorbance at 340nm due to the oxidation of NADH to NAD +
(Hamlyn, et al, 1982). A cytochemical method has also
been used to measure the inhibition of Na+K+ATPase. This
less direct method depends on the relationship between the
activities of two enzymes; stimulation of glucose-6-
phosphate dehydrogenase activity has been shown to
correlate with inhibition of Na+K+ATPase (Fenton, et al,
1982). Stimulation of glucose-6-phosphate dehydrogenase
was quantified by the densitometric measurement of colour
produced by the action of the enzyme from guinea pig kidney
slices. The ability of serum or tissue extracts to
inhibit the binding of [~^H]-ouabain to Na+K+ATPase has been
assessed using intact red blood cells (Devynck, et al,
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1983) and using partially purified enzyme (Kelly, et al,
1985).
In the studies presented in this thesis, samples were
tested for the ability to inhibit Na+K+ATPase using two
different, but direct, methods for measurement of enzyme
activity. In the first, the phosphate released by the
hydrolysis of ATP was measured by a colorimetric method,
and in the second method the hydrolysis of ATP was linked
to the oxidation of NADH by the enzymes lactate
dehydrogenase and pyruvate kinase.
In the colorimetric assay, samples were incubated with the
enzyme in triplicate with a single measurement of the
phosphate released. Although the -inter-assay CV had been
assessed over six assays as 8%, it was noted that during
the large study, comparing samples from normotensives and
hypertensives, that the CV deteriorated to 14% (16 assays
over a period of two months) . Variability in the
commercially prepared enzyme could have been a contributory
factor, this will be discussed later. The colorimetric
assay also depended on a 16h incubation of the enzyme
which, with hindsight, was an ill-advised choice of
incubation time. As it was unlikely that the enzyme was
still functioning after this length of time and the
stability of the Sep-Pak eluates was not known, it was an
error of judgement to use such incubation conditions.
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However, since controls were routinely included to measure
non-enzymic hydrolysis of ATP, and each sample measured
with this assay had its own triplicate control, the values
obtained were still a measure of the activity of the
enzyme. During the period when the colorimetric assay was
in use the Sep-Pak eluate was always reconstituted in its
own non-adsorbed filtrate (NAF). The intention was to
dilute the eluate in a matrix with similar characteristics
to plasma. For this reason the NAF was also measured in
the colorimetric assay to ensure that any inhibition which
was measured was due to the eluate and not substances
present in the NAF. As discussed later it was noted that
the NAF interfered in the assay in a manner which resulted
in an increase in the absorbance readings so any inhibition
which was measured was entirely due to the presence of the
eluate.
In addition to the problems outlined above, the
colorimetric assay was an extremely labour intensive method
because it depended on so many steps and, since as many
controls as samples were measured, it was only possible to
measure the inhibitory capacity of approximately 12 samples
per assay. The acquisition of a Cobas centrifugal
analyser provided the oppportunity to develop an enzyme-
linked assay which would permit the rapid analysis of a
substantially greater number of samples. This was of
particular importance when measuring the inhibitory
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capacity of the 80 fractions from a single HPLC separation.
The precision was excellent in the enzyme-linked assay and
the assay time was considerably reduced. This meant that
reliable values for the inhibitory capacity of samples were
obtained by a single measurement on each sample. By this
method as many as 26 samples could be assayed in a single
batch, which took approximately 10 minutes, compared with
12 samples in one and a half days for the colorimetric
method. The concentrations of ouabain standards in the
two assays indicated that the enzyme-linked assay was
apparently less sensitive; colorimetric assay 0.005-
25pmol/l, enzyme-linked assay 0.25-1000pmol/l. This was
because a much higher Na+K+ATPase concentration was used in
the enzyme-linked assay so the ratio of Na+K+ATPase to
inhibitor was lower thus more inhibitor was required to
inhibit the enzyme by the same amount. However, the
better precision and the smaller sample volume required in
the enzyme-linked assay compensated for this loss in
sensitivity. The enzyme-linked assay was capable of
detecting much smaller levels of inhibition. The inter-
assay CV over six consecutive assays was 8% in the
colorimetric assay compared with 1% in the enzyme-linked
assay. The detection limits for the two assays were,
therefore: 2% inhibition for the enzyme-linked assay and
16% for the colorimetric assay, equivalent to approximately
1-43
0.5 and 0.15jumol/l ouabain respectively. Detection limit
was defined as the concentration of ouabain which inhibited
the enzyme to a value which was two standard deviations
more than that of the uninhibited enzyme. Since the
enzyme-linked assay requires a much smaller sample (20pl
for a single assay) than the colorimetric assay (300pl for
triplicate assay and triplicate control), allowing greater
concentration of the sample, and the dilution in the
enzyme-linked assay was much less (20/250 compared with
50/1000), the difference in sensitivity becomes
unimportant.
The Na+K+ATPase used in both the colorimetric assay and the
enzyme-linked assay was a commercially prepared enzyme
obtained from Sigma Chemical Co. Ltd. (Poole, Dorset,
U.K.). Variation in the activity of this enzyme could
have contributed to the problems encountered in the
colorimetric assay. Although many workers in this field
use the same enzyme preparation it is possible to purify
Na+K+ATPase which has a much higher specific activity by
what appears to be a relatively simple method (Jprgensen,
et al, 1974). By preparing the enzyme "in house" it would
have been possible to greatly reduce the incubation time
required in the colorimetric assay.
Although it has been demonstrated in this thesis that Sep-
Pak eluates and HPLC fractions are capable of inhibiting
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Na+K+ATPase in the enzyme-linked assay it has not been
shown that the inhibition measured was due to a specific
action on the Na+K+ATPase. The linking enzymes, pyruvate
kinase and lactate dehydrogenase, were present at
concentrations twenty times that of the Na+K+ATPase,
however, if there was substantial inhibition of these
enzymes it could have been misinterpreted as inhibition of
the Na+K+ATPase.
If the substance of interest was truly acting on the
Na+K+ATPase then if the sample was added to the reaction
mixture in the presence of adenosine diphosphate and in the
absence of Na+K+ATPase there should be no inhibition of the
oxidation of NADH. Inhibition would be measured if the
sample is acting by inhibiting one of the linking enzymes.
It is also not known if the inhibition is reversible, an
important point if the sample is to be of biological
significance. Assuming that the substance acts in an
analogous way to the cardiac glycosides this could be
investigated by attempting to reverse the inhibition by
increasing the potassium concentration.
(b) Radioimmunoassay for Digoxin
Sep-Pak eluates showed cross-reactivity with digoxin
antibodies in both of the commercial digoxin RIA kits and
in the "in-house" digoxin RIA. The "in-house" method was
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used for the majority of the work contained in this thesis.
It was shown that the sample matrix affected the results
obtained with this assay (Fig.2.8, p65). When digoxin
standards were diluted in ammonium acetate (20mM, pH7.4) or
TTS, the buffer used in the enzyme-linked Na+K+ATPase
assay, the curve was displaced relative to the curve
obtained when standards were diluted in serum. Standards
diluted in RIA buffer were chosen for routine use because
they produced a curve which was similar to the serum curve
(see Fig.2.8, p65) .
Ammonium acetate was investigated as a possible standard
diluent because HPLC fractions were reconstituted in
ammonium acetate (20mM, pH7.4) in order that fractions
could be pooled and concentrated by freeze drying, if
required, since ammonium acetate would not be concentrated
by the freeze drying whereas non-volatile buffer salts
would be concentrated to levels at which they may interfere
in the assays. Reconstitution of HPLC fractions in
ammonium acetate meant that digoxin equivalents were not
quantitatively accurate, because of the curve displacement,
but since it was the elution profile which was of primary
interest, and not the absolute value of the peak heights,
this did not invalidate the results. However, in the
second large study comparing normotensive and hypertensive
subjects, eluates were reconstituted in RIA buffer to
ensure that quantitatively accurate results were obtained.
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(c) Sep-Pak Extraction
The Sep-Pak extraction method proved to be a simple and
rapid method for the preparation of samples. Ions pass
straight through the cartridges and, because the cartridges
were subsequently washed with water to remove very polar
substances, the final eluate should be free of ions. This
was verified when the lithium concentration was measured in
untreated plasma, the water wash and non-adsorbed filtrate
(NAF), and all lithium was accounted for in the NAF. The
concentration of metal ions in the sample would present a
possible source of interference in any Na+K+ATPase assay
and could result in artefactual findings. It has been
suggested that heating samples to temperatures above 40°C
and acidification could also produce artefacts (Tal, et al,
1986). Sep-Pak extraction is a more gentle and specific
method of extracting substances of interest than
deproteinisation of samples by acidification and boiling.
Using Sep-Pak cartidges, substances are extracted according
to their polarity.
In early work on this thesis, Sep-Pak eluates were
reconstituted in NAF in order to provide an internal
control but it was observed (see pll3) that when the bovine
concentrated eluate dilution curve was prepared in buffer
instead of NAF the inhibition obtained for a given
concentration factor was greater. This suggested that the
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NAF contained substances which interfered with the
Na+K+ATPase and so masked the inhibition present in the
sample. Following this observation all eluates were
subsequently reconstituted in buffer in order to avoid this
problem.
The recovery experiments using the Sep-Pak extraction
method were less than satisfactory. A contributory factor
was that recovery was assessed by the measurement of
Na+K+ATPase inhibition. These experiments could be
-3
improved by using [JH]-ouabain as the model and assesssing
the recovery by liquid scintillation. Until the factor
has been isolated, the measurement of recovery using
ouabain can only provide an approximate guide to the
recovery of the cardiac glycoside-like substance(s).
(d) High Performance Liquid Chromatography
The HPLC separation was extremely reproducible as assessed
by the pattern of peaks obtained by chromatography of
bovine adrenal cortex cytosol. One drawback of the method
was that the only "handle" on the substances of interest
was their inhibition of Na+K+ATPase and their cross-
reactivity with digoxin antibodies. This meant that the
result of a single HPLC separation was not known until the
fractions had been dried, reconstituted in buffer and
assayed, a process which took a minimum of 36 hours.
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Consequently, it took longer to optimise the method because
it was not possible to see the effect of altering
chromatographic conditions immediately.
(e) Isolated adrenal cell preparation
Isolated zona glomerulosa and zona fasciculata cells were
prepared from bovine adrenal glands and their
responsiveness to All and ACTH was measured. Both cell
types were dose-responsive to All and ACTH and the highest
concentrations were chosen for inclusion as controls in the
experiments on the effect of HPLC extracts on
steroidogenesis. There was considerable difference in the
size of the response between cells prepared on different
days; 2 and 3-fold stimulation of steroidogenesis on one
occasion, 2 and 6-fold stimulation on another. The
difference between cell preparations could have been a
consequence of events which occurred at the abattoir, for
example, the delay between death and removal of the adrenal
glands, and which were outwith my control.
(f) Radioimmunoassays for adrenal steroids
Two different separation methods were employed in the
adrenal steroid RIA's; preprecipitated double antibody and
charcoal separation. The two Cortisol assays employed
preprecipitated double antibody separation. Precision in
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these assays was reasonable except at low concentrations in
the sensitive assay where the low control (approx. 8nmol/l)
had a higher CV (28%). In the aldosterone assay the
control CV's had a mean of 12.5% and in the corticosterone
assay the low and medium controls had CV's less than 10%
but the high control had a CV of 21%. These values were
acceptable but if these assays were to be used for a much
longer study it would be desirable to attempt to improve
the precision in these assays.
2. INVOLVEMENT OF ENDOGENOUS CARDIAC GLYCOSIDE-LIKE
SUBSTANCES IN HYPERTENSION AND OTHER CONDITIONS
(a) Endogenous cardiac glycoside-like substances in
conditions other than hypertension
In the natriuretic hormone hypothesis, (de Wardener and
MacGregor, 1982), it is proposed that the stimulus for the
release of the hormone is central volume expansion.
Therefore, it is of interest that digoxin-like
immunoreactivity (DLIR) and Na+K+ATPase inhibition have
been measured in the serum of patients suffering from a
variety of conditions related by a disturbance of fluid
balance.
There have been many reports of the presence of DLIR in
serum from neonates (Pudek, et al, 1983), and in serum
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(Graves, et al, 1984) and amniotic fluid (Graves and
Wiliams, 1984) of 3rd trimester pregnant women. Pudek, et
al, (1983) also found no relationship between
dehydroepiandrosterone sulphate (DHEA-SO^) and DLIR,
although others have reported that DHEA-SO4 was responsible
for some of the DLIR present in plasma (Vasdev, et al,
1985). It has been reported that the levels of cross-
reactivity and inhibition in the amniotic fluid of third
trimester pregnant women were significantly correlated with
their diastolic blood pressure at time of amniocentesis and
hypertensive pregnant women had significantly higher levels
than normotensive women (Graves and Williams, 1984). This
is supported by recent work (Gregoire, et_ al, 1988) in
which a radioreceptor assay was used to measure a ouabain-
displacing factor present in urine. Normal pregnancy
significantly increased the levels of the factor and
greater increases were measured in the urine of subjects
who had pregnancy induced hypertension or pre-eclampsia.
However, Goodlin (1987) reported that the digoxin cross-
reactivity present in serum of women with pre-eclampsia was
often not much higher than that in serum of normotensive
pregnant women but if the pre-eclampsia was accompanied by
liver or renal dysfunction or expanded toxaemic syndrome
the serum levels of DLIR increased occasionally to values
which were in the therapeutic range for digoxin. The
difference between the results of Gregoire, et ad, (1988)
and Goodlin (1987) could be because they are using
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different assays or because they were investigating
different body fluids.
Raised levels of digoxin cross-reactivity have also been
reported in patients with liver disease (Greenway and
Nanji, 1985; Nanji and Greenway, 1985) and different
values for the DLIR content of a sample were obtained with
different digoxin assay kits (Greenway and Nanji, 1985).
Higher levels of DLIR were reported when liver disease was
accompanied by ascites and oedema (Nanji and Greenway,
1986) which could be related to the volume expansion
associated with these conditions.
It has been suggested that the hyponatraemia which often
follows aneurysmal subarachnoid haemorrhage could be due to
the release of a digoxin-like natriuretic factor, possibly
as a result of hypothalamic damage (Wijdicks, et al, 1987).
It was shown that plasma volume was expanded in patients
with acromegaly (Deray, et al, 1987), a condition in which
there is excess production of growth hormone, and that
there was a significant correlation between plasma volume
and the capacity of serum from these patients to inhibit
Na+K+ATPase.
It has been known for some time that there are sodium
transport abnormalities associated with uraemia (Cole,
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1973; Edmondson, et ad, 1975a) and that uraemic serum
contained a factor which inhibited sodium efflux in
erythrocytes (Kramer, et al, 1976) and inhibited brain
Na+K+ATPase (Minkoff, et al, 1972). It was subsequently
reported that falsely raised (Belpaire, 1975) or false
positive (Graves, et al, 1983) digoxin levels were measured
in patients with renal failure. Graves, et al, (1983)
reported that as many as 60% of patients had false positive
values, however, Greenway and Nanji (1986) found only a 23%
false positive rate which could be due to batch-to-batch
differences in antibody since some kits were obtained from
the same manufacturers as Graves, et al.
The activity of erythrocyte Na+K+ATPase in patients with
renal failure was asessed by Izumo, et al, (1984) using a
p £ODRb uptake method. In this method, the active
p C.
transport of [°°Rb] into the cell reflects potassium
transport by the enzyme and thereby provided a measure of
the Na+K+ATPase activity. Dialysis improved the activity
of the enzyme, which was 30% of the control values before
dialysis, and incubation of normal cells in pre- and post-
dialysis uraemic serum demonstrated that the inhibition of
the enzyme was caused by a humoral factor. Izumo, et al,
(1984) reported no difference in the number of pump sites,
as assessed by [ H]-ouabain binding, but Cheng, et al,
(1984) suggested that a decrease in the number of pump
sites was responsible for the high erythrocyte
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intracellular sodium measured in 16 of the 45 end stage
renal patients on dialysis that they studied.
Early reports of transport abnormalities in erythrocytes of
renal failure patients could be explained by the presence
of Na+K+ATPase inhibitors in their serum. Studies of the
effect of dialysis on the levels of these inhibitors have
produced disparate results. Kelly, et al, (1986a) report
that the amount of inhibition increased acutely during
dialysis and that chronic dialysis returned values to the
normal range but Deray, et al, (1986), report that dialysis
acutely decreased the inhibitory activity in serum of renal
failure patients to levels found in normotensive control
patients.
The presence of cardiac glycoside-like activity in serum in
conditions associated with volume expansion lends support
to the view that endogenous cardiac glycoside-like
substances could be important in volume homeostasis and not
only in the development and maintenance of hypertension
(Kelly, et al, 1986a). Kelly, et al, (1986a) measured
digoxin cross-reactivity and Na+K+ATPase inhibition in
extracts of plasma obtained from normotensives, essential
hypertensives with normal renal function, hypertensives
with moderate chronic renal failure (CRF) and patients with
end-stage renal failure on chronic haemodialysis. The
hypertensives with moderate CRF had greater levels of
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Na+K+ATPase inhibitor and digoxin cross-reactivity than
normotensives. Na+K+ATPase inhibitor was greater in
hypertensives with moderate CRF than in hypertensives with
normal renal function who in turn had higher levels than
normotensives but patients on dialysis had levels similar
to those of the normotensives, although dialysis acutely
raised plasma Na+K+ATPase inhibitor levels. The
substances responsible for the increased Na+K+ATPase
inhibition were identified as NEFA's which had been
designated EI^ and EI3 in previous work (Kelly, et al,
1985). In agreement with the results from the comparison
of normotensive and hypertensive subjects reported in this
thesis, Kelly, et al, found no correlation between blood
pressure and Na+K+ATPase inhibitor or digoxin cross-
reactivity in these groups of subjects.
A similar study by Deray, et al, (1986) also reported that
hypertensives had higher levels of Na+K+ATPase inhibitor,
as measured by tritiated ouabain binding, than
normotensives but that normotensives with a family history
of hypertension had a higher level than normotensives
without such a family history. Again, no correlation was
observed between Na+K+ATPase inhibition and blood pressure
nor did inhibition correlate with plasma renin activity,
however, a slight but significant correlation was obtained
between inhibition and urinary sodium excretion, again
supporting an association of DLIR with volume homeostasis.
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Deray, et al, found that patients with chronic renal
failure, who did not require dialysis, had Na+K+ATPase
inhibitor levels which were similar to those of the
normotensive control group but Kelly, et al, reported
raised levels in such subjects. It was likely that the
difference between these results was due to the fact that
the patients studied by Deray, et al, were normotensive but
those of Kelly, et al, were hypertensive which would
suggest that the presence of the Na+K+ATPase inhibitor was
associated with their hypertension. As discussed above,
these two studies disagree about the effect of dialysis on
Na+K+ATPase inhibitor levels. Kelly, et al, (1986a)
report that dialysis acutely raises Na+K+ATPase inhibitor
levels whereas Deray, et al, (1986) report a decrease after
dialysis. One reason why these authors have reached
different conclusions may be because they are treating
their samples differently. Kelly, et al, are performing a
certain amount of extraction prior to assay but Deray, et
al, are using a 1/20 dilution of untreated plasma.
(b) Endogenous cardiac glycoside-like substances in
hypertension
According to the natriuretic hormone hypothesis (de
Wardener & MacGregor, 1982), natriuretic hormone should be
present in greater amounts in essential hypertensives as
compared with normotensives. There have been several
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reports which show that hypertensives have a raised level
of Na+K+ATPase inhibitor in their plasma (Hamlyn, et al,
1982; MacGregor, et al, 1981; Poston, et al, 1981;
Sagnella, et al_, 198 6).
In the studies contained in this thesis, the inhibitory
capacity of extracts from plasma samples from normotensives
and hypertensives was assessed initially using a
colorimetric Na+K+ATPase assay. A pilot study comprising
plasma samples from 12 normotensives and 12 hypertensives
demonstrated that it was possible to extract substance(s)
which would inhibit Na+K+ATPase using Sep-Pak C^g
cartridges. However, in the larger study (32
normotensives, 46 hypertensives) no measurable inhibition
was extracted from the plasma. One reason for the
different result obtained in the second study may have been
a difference in the biochemical parameters of the two
groups of hypertensives. Unfortunately, as discussed
later, no such data were available. The main reason for
the different results was probably methodological. The
difference in the concentration factor between the two
studies may have contributed to the different results
obtained; in the pilot study the eluate was reconstituted
in 350pl whereas in the larger study it was reconstituted
in 500pl to allow sufficient eluate for measurement of
digoxin cross-reactivity as well as Na+K+ATPase inhibition.
The results from this study were not evaluated until after
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all the samples had been measured so no action was taken to
improve the concentration factor, although it would not
have been possible to take remedial action because the way
the work had been organised all samples had been extracted,
pipetted into assay tubes and frozen before the first batch
of samples was assayed for inhibitory activity. In
subsequent work, using the enzyme-linked assay, raw data
was examined immediately so this situation would never be
repeated. Although there was no significant difference
between the eluates and the NAF in the study, some eluates
did show very small amounts of inhibition. However, these
values were so small that they were encompassed within the
errors in the assay. As the eluates were reconstituted in
NAF, and NAF has been noted to interfere in the Na+K+ATPase
assay, it is possible that the NAF masked any small amount
of inhibition which was present. A very small amount of
inhibition could also have been obscured by variation the
recovery from Sep-Pak cartridges.
Although the eluates in the large study did not contain any
measurable inhibitory activity they did cross-react with
digoxin antibodies. This digoxin cross-reactivity did not
correlate with mean arterial pressure and there was no
significant difference between the results obtained for
normotensives and hypertensives.
When the larger study was repeated, using the enzyme-linked
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Na+K+ATPase assay, measurable inhibition was present in the
eluates. There were two possible reasons for the
different results with the two assays. First, it was
possible to reconstitute the eluate in a considerably
smaller volume; 170pl compared with 500pl when the
colorimetric Na+K+ATPase assay was used, thus increasing
the concentration factor achieved and so improving the
resolving power. Secondly, the eluates were reconstituted
in buffer, instead of NAF, because it had been observed
that NAF contained substances which were capable of
interfering in the Na+K+ATPase assay and masking all or
part of the inhibition. Not only were all eluates capable
of inhibiting Na+K+ATPase but they also showed cross-
reactivity with digoxin antibodies. However, there was no
correlation between the two activities supporting the idea
that more than one substance was extracted. Furthermore,
there was no correlation between mean arterial pressure and
inhibition or cross-reactivity when expressed as ouabain or
digoxin equivalents respectively.
Separation on HPLC, discussed later, provides a possible
explanation for the lack of correlation between the
inhibitory activity and cross-reactivity measured in the
samples from normotensive and hypertensive patients. On
HPLC the inhibitory activity and cross-reactivity
separated into several fractions but fractions possessing
both activities eluted in only two positions. It is
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possible that the total concentrations of inhibitory-
activity and cross-reactivity could alter independently of
one another so further refinement of the Sep-Pak separation
method would be necessary to determine whether the
fractions which show both inhibition and cross-reactivity
had altered in concentration.
In their study of plasma samples from normotensives and
hypertensives, Hamlyn, et al_, (1982) also found no
correlation between inhibition and cross-reactivity
although they did find a correlation between the inhibition
and blood pressure. The enzyme-linked Na+K+ATPase assay
used in this thesis was based on the method used by Hamlyn,
et al, but plasma sample treatment was different; Hamlyn,
et al, deproteinised plasma by acidification and heating,
whilst the Sep-Pak extraction method concentrated
substances which had similar polarities, so the extracts
tested in the assay by Hamlyn, et al, (1982) were likely to
contain different substances from those in the Sep-Pak
extract.
Blood pressure has also been correlated with levels of
digoxin cross-reactivity in monkeys (Gruber, et al, 1982)
and with the ability to inhibit ouabain binding to
erythrocytes in hypertensive patients (Sagnella, et al,
1986). MacGregor, et al, (1981) reported that serum from
hypertensives contained more inhibitory activity, as
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assessed by the capacity to stimulate glucose-6-phosphate
dehydrogenase, than serum from normotensives. However, my
findings are in agreement with those of Kelly, et al,
(1986a) and Deray, et al, (1986) who found no correlation
between ouabain-like activity and mean arterial pressure.
The different conclusions, regarding the relationship
between cardiac glycoside-like activity and blood pressure,
are a consequence of the lack of concensus about sample
treatment and measurement of cardiac glycoside-activity and
the problems associated with studying the effect of serum
or plasma on the assays. Serum and plasma contain many
substances which, if concentrated sufficiently, will
interfere in assays for cardiac glycoside-like activity.
For example, Na+K+ATPase can be inhibited by potassium
(Glynn and Karlish, 1975) or NEFA's (Bidard, et al, 1984),
endogenous steroids could cross-react in immunoassays. In
the literature discussed above, workers using similar
assays but different sample preparation arrived at
different conclusions. Both Deray, et al, (1986) and
Sagnella, et al, (1986) were measuring ouabain binding to
red blood cells by similar methods but whereas Deray, et
al, boiled the plasma, then assayed it at a 1/20 dilution
and found no correlation with blood pressure, Sagnella, et
al, used Dowex resin to remove potassium ions, a possible
source of inhibition, and noted a correlation of ouabain-
like activity with systolic blood pressure. Another
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possible source of difference was subject selection.
Deray, et al, suggested that their results differed from
those of Hamlyn, et al/ (1982) because the sex and ethnic
background of the two groups of subjects were different.
It has been shown by several workers (Devynck, et al/ 1983;
Cloix, et al, 1983; Deray, et_ a_l, 1986; Kelly, et al,
1986a) that there are not simply two separate populations;
normotensives and hypertensives, but that there is a
spectrum of values which can be divided up into
hypertensives, normotensives with a family history of
hypertension and normotensives. This should not
necessarily be surprising since blood pressure follows a
normal' distribution within a given population. Therefore,
if this factor contributes to the raised blood pressure of
some of the population then it should not be expected to be
either simply present or absent. The results contained in
this thesis would support this view since no significant
difference was found between normotensives and
hypertensives. Insufficient information was available to
divide the normotensives into those with a family history
of hypertension and those without.
As discussed earlier, it has been reported that raised
levels of cardiac glycoside-like activity are present in
conditions associated with volume expansion. For this
reason it would have been valuable to have information
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about the renal and liver function of the subjects. The
renin status of the subjects would also have been of
interest. If some of the subjects had low-renin
hypertension the natriuretic hormone would be expected to
be present at higher concentrations than in subjects whose
renin levels were normal. However, Deray, et al, (198 6)
did not find a correlation between inhibition of [ H]—
ouabain binding and renin activity.
Animal models of hypertension have been investigated for
the presence of ouabain-like substances but these models,
like human essential hypertension, have different
characteristics (Genetic rat models for hypertension,
1987); some are volume expanded, others are not, some are
spontaneously hypertensive, others require a high salt diet
to initiate the development of hypertension. However,
cardiac glycoside-like activity has been measured in a
number of different rat models. Lichtstein, et al,
(1985a) found no difference between the amount of inhibitor
found in HPLC purified extracts from the serum of Sabra
hypertension prone and hypertension resistant rats. In
the DOCA-salt rat, ouabain-like activity, as measured by
[ H]-ouabain displacement from brain synaptosomes, was
greatest in DOCA-salt rats, less in salt treated rats and
least in untreated rats (Kojima, 1984). Digoxin cross-
reactivity was observed in DOCA-salt rats only. This
activity was related to the blood pressure since the blood
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pressure was significantly higher in DOCA-rats than in
control and salt treated rats. It has also been shown
that injection of digoxin antibodies into DOCA-salt
hypertensive rats results in a reduction in their blood
pressure (Kojima, et al_, 1 982) .
In recent work with the Milan hypertensive strain, it was
shown that raised levels of an endogenous Na+K+ATPase
inhibitor were present in the plasma of young genetically
hypertensive rats even before there was any increase in
their blood pressure (Holland, et al, 1987). In this
strain of rat it has been previously demonstrated that,
when kidneys were transplanted from young rats before they
had developed high blood pressure into rats which should
remain normotensive, the hypertension "followed the kidney"
and the recipient rat developed high blood pressure
(Bianchi, et_ al_, 1974). The work of Holland, et al,
(1987) supports the hypothesis that a genetic kidney defect
results in stimulation of the release of an endogenous
Na+K+ATPase inhibitor which leads to the development of
hypertension.
Holland, et _aly were using the cytochemical assay in which
inhibition of Na+K+ATPase was measured by its ability to
stimulate glucose-6-phosphate dehydrogenase. This assay
was also used by Millett, et al, (1986), who found greater
quantities of glucose-6-phosphate dehydrogenase stimulating
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activity in the plasma and acetone extract of hypothalami
from spontaneously hypertensive rats as compared with
normotensive rats. Millett, et ad suggest that the
hypothalamus could be a source of the inhibitory substances
found in the plasma. However, it was reported recently
(Doris, 1988) that plasma levels of a digoxin-like
substance decreased following adrenalectomy in the rat
which suggests that the adrenal gland could also contribute
to the plasma concentration of digoxin-like substances.
This work supports the results reported in this thesis and
contrasts with the report that the adrenal gland was devoid
of inhibitory activity as assessed, indirectly, by the
ability to stimulate glucose-6-phosphate dehydrogenase
(Alaghband-Zadeh, et ad, 1983).
3. CONCENTRATION AND SEPARATION OF A FACTOR FROM SERUM
The digoxin cross-reactivity and inhibitory activity
extracted from plasma, using the Sep-Pak extraction
technique, was concentrated and then separated into several
active fractions by HPLC.
(a) Concentrated Eluates
To investigate the dose-response of the inhibition and
cross-reactivity, the Sep-Pak eluates were further
concentrated by application to a second Sep-Pak cartridge.
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These concentrated eluates were prepared from a
considerably larger volume of plasma than the single
patient samples used for the comparison of normotensives
and hypertensives. When pooled normotensive plasma was
concentrated 120-fold the beginning of a dose-response
curve was obtained for inhibition. Polycythaemic plasma
was concentrated to a greater extent (344-fold) and did not
show any dose-response for inhibition but a curve was
obtained for cross-reactivity with digoxin antibodies.
This was the first indication that the inhibition and
cross-reactivity could be dissociated from one another and
is consistent with the finding, reported earlier (pl58)
that there was no correlation between the inhibitory
activity and cross-reactivity extracted from normotensive
and hypertensive subjects. It should be noted that since
the eluates in these studies were reconstituted in NAF some
of the inhibition may have been masked.
It was difficult to obtain large volumes of human plasma so
bovine serum was investigated for the presence of ouabain-
like substances since it was available in large volumes
from a local abattoir and it has been reported that the
plasma from a volume expanded cow contained natriuretic
activity (Lichardus, et al, 1968). A large volume
(approx. 3.41) of bovine serum was concentrated on Sep-Pak
cartridges to give a final concentration factor of 400.
Dilutions of this produced a dose-response curve in both
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the Na+K+ATPase assays and in the digoxin RIA.
When the values obtained using the colorimetric and the
enzyme-linked Na+K+ATPase assays were compared the %
inhibition for a given concentration factor were identical.
Since the ouabain standards used to quantify the inhibition
in the two assays cover different ranges, the inhibitory
activity would be assigned different ouabain equivalents
depending on the assay used.
The digoxin cross-reactivity of the bovine serum
concentrated eluate was assayed using several different
commercial kits and the "in-house" method. The eluate
produced measurable cross-reactivity in all kits but to a
different extent depending on the assay. The difference
in cross-reactivity reflects the different affinities of
the antibodies used in each method.
(b) HPLC of bovine serum eluate
When the eluate prepared from bovine serum was separated
using HPLC on an octadecylsilane column, fractions capable
of Na+K+ATPase inhibition eluted as three peaks and
fractions which cross-reacted with digoxin antibodies
eluted as three peaks. The largest peak of Na+K+ATPase
inhibition did not show any cross-reactivity but the other
two peaks, which eluted at the beginning of the gradient,
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had both inhibitory activity and cross-reactivity. The
levels of inhibition were very low and to obtain peaks with
a higher activity it would be necessary to repeat this
using an eluate which was more concentrated. As there was
insufficient sample to repeat the separation, it was not
possible to make any comment regarding the reproducibility
of this pattern of peaks. However, HPLC separation of
adrenal cortex cytosol eluate, which will be discussed
later and which used the same equipment, protocol, solvents
and acetonitrile gradient was very reproducible (10 runs).
The HPLC profile obtained for the concentrated serum could
be used as a guide to indicate the acetonitrile
concentrations suitable for the elution of the two peaks
showing both inhibitory capacity and cross-reactivity from
Sep-Pak cartridges. Having extracted and concentrated the
substances in this way they could then be applied,
separately, to the HPLC column and eluted using a suitable
gradient. If this proved successful with bovine serum the
Sep-Pak method could then be applied to samples from
hypertensive and normotensive subjects.
Tal, et al, (1986) have also extracted a substance from
bovine plasma which was capable of inhibiting Na+K+ATPase.
After exhaustive solvent extraction and HPLC on an amino
column a single peak was obtained. They were careful in
their protocol to keep the plasma at temperatures less than
40°C throughout the extraction and suggest that the
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multiple peaks reported by other workers could be artefacts
caused by the raised temperature during sample preparation.
My results do not lend support to this idea, since the
samples were never boiled and the methanol was evaporated
off the eluate at a temperature of 37°C, but should be
considered in the interpretation of other studies in which
plasma was heated and the ouabain-like activity was
subsequently separated into several active fractions.
Artefacts could also arise because substances normally
present in plasma have been concentrated to abnormally high
levels e.g. potassium, NEFA's.
Plasma collected from normotensive subjects was boiled and
separated on HPLC by Kelly, et al, (1985). This resulted
in the isolation of 4 different peaks; labelled EI^, EI2,
EIIR]_/ which were later identified as NEFA, in the case
of EI^ and EI3, and half NEFA and half lysophospholipid for
EI2- IR]! showed only cross-reactivity and was thought to
be due to some NEFA but mostly due to hydrocortisone or
other endogenous steroids. Crabos, et al, (1984) also
report that plasma could be separated into several active
peaks of activity using HPLC, as could urine. Ouabain-
like activity in plasma has also been separated into
several peaks using anion exchange chromatography (Cloix,
et al, 1984). These results form further support for the
idea that more than one substance is responsible for the
activity present in plasma. When pooled plasma from DOCA-
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salt hypertensive rats was separated by gel filtration on
Sephadex G-25, two peaks were obtained; one peak showed
inhibition and cross-reactivity whilst the other would only
cross-react, suggesting that at least two substances were
responsible for the cross-reactivity present in the plasma
of DOCA-salt rats (Kojima 1984). The antibody used by
Kojima was reported to show no cross-reactivity with
adrenal steroids (Kojima, 1984) so it is unlikely that the
peak which exhibited only cross-reactivity was due to DOCA.
As it is proposed that natriuretic hormone is released in
response to volume expansion (de Wardener, 1982), several
groups have studied animals which have been experimentally
volume expanded. Gruber, et al, (1980) found more
inhibitory activity and digoxin cross-reactivity in the
serum of volume expanded dogs than in hydropenic dogs.
Tamura, et al, (1985) identified the substances responsible
for some of the inhibitory activity in the serum of volume
expanded hogs as linoleic and oleic acid. These NEFA were
reported to be present in the HPLC fractions isolated by
Kelly, et al, (1986b). Using column chromatography,
reverse phase and gel filtration HPLC, Goto, et al, (1988)
isolated a factor from volume expanded dog plasma which had
similar polarity to ouabain and had a molecular weight,
according to fast atom bombardment mass spectrometry (FAB
mass spec.), of around 343Da. The elution pattern of NEFA
on reverse phase HPLC was different to that of the factor
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they isolated and NEFA were not found to have any effect on
their assay systems so it was considered unlikely that
their isolated substance was a NEFA.
Prior to dialysis, renal patients are volume expanded.
Dasgupta, et al, (1987) extracted two fractions, from the
plasma ultrafiltrate obtained during dialysis, which showed
both inhibition and cross-reactivity. Both of these
fractions were analysed by FAB mass spec, and both had a
dominant component at 531Da. One of these fractions was
further analysed and identified as a novel compound derived
from lysophosphatidyl serine with a novel 19:4 fatty acid
side chain (Dasgupta, et al, 1988). However, the authors
did not discount the possibilty that this compound was an
artefact of the isolation procedures which comprised
alkaline solvent extraction followed by HPLC.
Extraction with acetone has been shown to produce artefacts
under certain conditions (Whitmer, et al, 1982). Using
acetone extraction, a digoxin-like substance was isolated
from guinea pig brain (Fishman, 1979) and Haupert and
Sancho (1979) extracted a substance with similar properties
from bovine hypothalamus. Millett, et al, (1987) reported
that greater levels of inhibitory substance were present in
the hypothalami of SHR compared with the hypothalami of the
normal cpntrols, in this work acetone was employed in the
extraction procedure.
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Haupert, et al, (1984) modified their extraction procedure
and demonstrated that they had isolated a reversible
inhibitor of Na+K+ATPase from bovine hypothalami which was
ft ft ft
shown subsequently to inhibit Rb uptake and [JH]-ouabain
binding to intact, cultured renal epithelial cells
(Cantiello, et al, 1988). Cultured rat hypothalamic cells
have been employed to avoid the problems associated with
tissue extraction. These cells were found to release a
Na+K+ATPase inhibitor which eluted as a single peak from
HPLC (Morgan, et al, 1985) thus supporting the idea that
the endogenous cardiac glycoside-like substance(s) is
produced in the hypothalamus. This factor was recently
shown to produce a concentration-dependent increase in
tension in de-endothelialised rabbit aortic strips (Mir, et
al, 1988); an effect which could be reversed by washing.
This factor also potentiated the vasoconstrictor effect of
noradrenaline and caused greater calcium retention than
control medium. If it is demonstrated that this factor is
released into the circulation and has a natriuretic effect
it could well be the putative hormone which has been
sought.
4. BOVINE ADRENAL CORTEX
(a) HPLC of adrenal cortex cytosol eluate
Digoxin cross-reactivity has been reported in the adrenal
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gland of the rat (Schreiber, et. ad, 1981a) and of the
rabbit (Schreiber, et al, 1981b). In the rabbit, two
fractions were separated by thin layer chromatography which
showed both cross-reactivity and the ability to inhibit
®^Rb uptake into erythrocytes (Schreiber, et al, 1981b).
Organ surveys in rats have found the highest levels of
digoxin cross-reactivity in the adrenal gland (Castenada-
Hernandez and Gotfraind, 1984; Valdes, et al, 1985).
However, the adrenal gland has been reported to be devoid
of the ability to inhibit Na+K+ATPase, as assessed by the
ability to stimulate glucose-6-phosphate dehydrogenase
(Alaghband-Zadeh, et_ al_, 1983), and of all the organs
surveyed by these authors only the hypothalamus contained
stimulatory activity. Two more recent organ surveys,
published after completion of work on this thesis, have
confirmed that the adrenal gland does contain activity.
Rauch and Buckalew (1988) reported that, of the peripheral
organs, the adrenal gland contained the most activity, as
measured as the ability to inhibit [ H]-ouabain binding to
red blood cells. Various regions of the brain were also
examined and the striatum was reported to have similar
concentrations of activity to the adrenal gland. Another
recent organ survey reported that of all tissues, including
the brain, only the adrenal gland showed digoxin cross-
reactivity (Doris, 1988). The difference between the
results obtained in these organ surveys may due to the
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different extraction procedures or due to the different
assays used.
To investigate whether the adrenal gland contained
substances capable of both inhibitory activity and cross-
reactivity, adrenal cortex cytosol was prepared and
separated using the Sep-Pak extraction procedure. It was
observed that Sep-Pak eluate was capable of inhibiting
Na+K+ATPase and cross-reacting in the digoxin RIA in a
dose-dependent manner. The presence of such high levels
of inhibitory activity and cross-reactivity in the adrenal
cortex suggested that it may be a suitable model for
investigation of extraction methods intended for use on
plasma samples, however the HPLC profile obtained from
adrenal preparations was not sufficiently similar to that
of serum for this to be the case (Fig.3.6 and Fig.3.8).
HPLC of bovine adrenal cortex cytosol resulted in several
peaks of inhibition and cross-reactivity which eluted in
different positions to those obtained by HPLC separation of
serum. The pattern of peaks was extremely reproducible
(10 runs) and in only two positions did the inhibition and
cross-reactivity co-elute. This is similar to the serum
results, in that two co-eluting peaks were obtained,
however the activity from serum eluted in different
positions. Fractions with Cortisol cross-reactivity
eluted in the same position as those with digoxin cross-
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reactivity except for one extra Cortisol peak. The
largest Cortisol peak was thought to be native Cortisol and
eluted immediately before the fractions of interest.
Endogenous digitalis-like factors purified from plasma have
been identified as NEFA, phospholipid and endogenous
steroids (Kelly, et al, 1986b). For this reason fractions
from the HPLC of bovine adrenal cortex were assayed for
NEFA using a commercial kit. NEFA eluted in several peaks
before and one peak after those of interest. The last
peak of NEFA co-eluted with a peak of inhibition which did
not show any cross-reactivity. Since the kit which was
used was capable of detecting several different NEFA's, and
the values obtained for the HPLC fractions were all less
than the bottom standard it would appear that the HPLC
method concentrates the small quantity of NEFA extracted on
the Sep-Pak cartidges into discrete peaks thus separating
them from the substances of interest.
Cloix, et al, (1985) have identified a substance with
digoxin-like characteristics which appears to be an amino-
glyco-steroid. The HPLC peak fractions could be steroid¬
like since they cross-react in both the Cortisol and
digoxin RIA's and so could be structurally similar to these
molecules.
The two peaks from HPLC of bovine adrenal cortex were
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subjected to tryptic digestion and heat (80°C, lOmin).
Heat had no effect on either of the peaks but trypsin
approximately halved the activity of both peaks. This
would suggest that the peaks contain a heat stable peptide.
Unfortunately there was insufficient sample to measure the
digoxin cross-reactivity after tryptic digestion which
would have helped to resolve the question of whether there
was more than one substance responsible for the cross-
reactivity and the inhibition caused by the peaks. It is
possible that the inhibition may be due to several
substances in both peaks, only one or some of which is
susceptible to trypsin, however, all would appear to be
capable of withstanding 80°C for 10 min.
In support of the findings of this thesis is the report of
Tamura, et ad, (1987) who purified a single peak of
ouabain-like activity from whole bovine adrenal glands by
homogenisation in methanol followed by HPLC using several
different columns and solvent conditions. This factor
inhibited Na+K+ATPase, displaced [^H]-ouabain and inhibited
o r
[°DRb]-uptake into red blood cells. Dose-response curves
for these activities were parallel to those of ouabain and
the inhibition of Na+K+ATPase by the factor was shown to
have the same dependence on potassium concentration as
ouabain. Although the data was not given, it also
apparently cross-reacted with digoxin antibodies and the
activity was unaffected by incubation with pronase E,
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trypsin, deoxyribonuclease I, ribonuclease A, phospholipase
C, weak alkali or heat treatment but was destroyed by
hydrochloric acid (6M, 115°C, 21h). FAB mass spec,
indicated a molecular mass of 336Da.
It is interesting that Tamura, et. al, found only a single
peak whereas in my work the inhibition and cross-reactivity
co-eluted in two peaks. It could be that one of the peaks
would not displace ouabain from Na+K+ATPase or inhibit ®^Rb
uptake from red blood cells. Clearly this would merit
further investigation. Since the peak fractions have been
subjected only to one HPLC separation it is likely that
there is more that one substance present in each peak, an'
assumption borne out by the results from the tryptic
digestion, it might be that one of the peak fractions
contains the factor isolated by Tamura, et al^. Resistance
to tryptic digestion was also a characteristic of the
hypothalamic factor recently shown to"increase the tension
of de-endothelialised aortic strips (Mir, et al, 1988) and
it is possible that the factor in the adrenal gland and in
the hypothalamus are related, although Tamura, et al, do
not consider their adrenal factor to be a peptide whereas
the hypothalamic factor of Mir, et al, is thought to be a
peptide.
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(b) Effect of adrenal peak fractions on steroidogenesis in
isolated bovine adrenal cortex cells
The HPLC peak fractions produced as much as 50-fold
stimulation of steroid production in isolated adrenal
cells. The first peak stimulated aldosterone production
only, but the second peak stimulated Cortisol,
corticosterone and aldosterone production. The effects
that the HPLC peaks had were in contrast to the effect of
ouabain on steroidogenesis. Ouabain has been reported to
inhibit aldosterone synthesis in bovine zona glomerulosa
cells (Elliot et al, 1986) and in dog adrenal cortex slices
(Cushman, 1969) but either stimulated or inhibited
steroidogenesis in rat zona glomerulosa cells depending on
the concentration used (Schriffrin, et al, 1981; Brayley,
— R
and Williams, 1978). In rat zona glomerulosa cells, 10 M
ouabain stimulated basal aldosterone production and
corticosterone production but concentrations greater or
less than this had no effect on basal steroid production
_ C
(Brayley and Williams, 1978). 10 M ouabain increased
aldosterone production in All-stimulated rat zona
glomerulosa cells above the already raised levels, but
concentrations greater than this inhibited the response to
All, ACTH and potassium (Brayley and Williams, 1978;
Schriffrin, et^ al, 1981). The adrenal cell work reported
in this thesis was performed on bovine material and so
according to the results of Elliot, et al, (1986) a
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substance with ouabain-like qualities might be expected to
inhibit steroidogenesis. Since the opposite was found to
be the case a possible explanation could be that the
ouabain-like substances present in the HPLC peak fractions
act on bovine adrenal cells in manner analagous to that of
ouabain on rat adrenal cells and that, at the concentration
tested, they stimulate steroidogenesis but at a different
concentration they would inhibit steroidogenesis.
The stimulation obtained with these substances was far
greater than the stimulation due to All or ACTH, which may
indicate that the peaks contain steroid precursors of those
which were measured. To elucidate whether the substances
present in the HPLC fractions act as agonists, cAMP and
cGMP .could be measured following incubation of adrenal
cells with the fractions. The concentration of the second
messenger would be expected to increase if the cardiac
glycoside-like substances are acting as agonists through
interaction with receptors on the cell. If the substances
in the HPLC fractions are steroid precursors then the
concentration of second messenger would not be expected to
increase.
Another complication was the cross-reactivity of the HPLC
fractions with the antibodies for Cortisol and
corticosterone. The cross-reactivity was so great that
some of the supernatants from the cell incubations had to
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be assayed at dilutions as high as 1/1000 in the
corticosterone assay and 1/100 in the Cortisol assay.
Cross-reactivity with the aldosterone assay was minimal and
presented no problem. There was insufficient sample to
perform dilution curves in the Cortisol and corticosterone
assays to check that the cross-reactivity diluted out in
parallel with the native steroid. This meant that the
absolute values for the stimulation would not be as great
as they appear if the cross-reactivity did not dilute out
in parallel.
Further study of the activity in the adrenal gland could
follow several lines. The Sep-Pak extraction method could
be modified by using the acetonitrile concentrations at
which the peak fractions elute from the HPLC column in
place of methanol. This would provide a better way of
concentrating the substances of interest prior to HPLC
separation. HPLC conditions could also be altered by
using either the same type of column with a different
gradient system or on a different type of column which
would separate substances according to, for example,
charge. By comparing the elution position from the HPLC
column of tritiated steroids with that of the peak
fractions it would be possible to conclude whether or not
native steroids were responsible for the activities
measured. If the HPLC fractions contain cardiac
glycoside-like substances then they should be capable of
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inhibiting the binding of tritiated ouabain to either
purified Na+K+ATPase or red blood cells therefore future
work should include the development of a radioreceptor
assay.
5. CONCLUSION
The major problem in attempting to isolate cardiac
glycoside-like substances has been that it was necessary to
concentrate the sample several hundred fold thus making it
more likely that artefacts could be produced. Artefacts
could arise because substances normally present in tissue
or plasma have been sufficiently concentrated to inhibit
the enzyme, for example, potassium (Glynn and Karlish,
1975) or ascorbic acid (Ng, et al, 1985). Some compounds
which have been shown to possess ouabain-like qualities
include steroid compounds such as chlormadinone acetate
(Hnatowich and LaBella, 1984), dehydroepiandrosterone
sulphate (Vasdev, et al, 1985), methylguanidine (Minkoff,
et al, 1972), non-esterified fatty acids (Kelly, et al,
1986b; Bidard, et. ad, 1984); Tamura, et_ aJL, 1985) and a
novel cytochrome P45Q metabolite (Schwartzman, et al,
1985). By using cultured hypothalamic cells (Morgan, et
al, 1985) the problems of producing artefacts are reduced.
However, there is now a considerable body of evidence which
supports the existence of endogenous Na+K+ATPase inhibitors
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and the involvement of these substances in hypertension and
certain conditions where there is a disorder of fluid
balance. Since it is likely that essential hypertension
has several different causes it is plausible that the
natriuretic hormone hypothesis provides an explanation of
one of the ways in which hypertension may develop and be
maintained. Much evidence supports the idea that the
endogenous Na+K+ATPase inhibitors are produced by the
hypothalamus and several groups have isolated Na+K+ATPase
inhibitor from this organ (Haupert, et ad, 1984; Millett,
et al, 1986; Morgan et al, 1985;). However, cardiac
glycoside-like substances have also been isolated from the
adrenal gland (Tamura, et al, 1987), the heart (Fagoo, et
al, 1986), as well as urine (Cloix, et al, 1985), plasma
(Tal, et al, 1986) and amniotic fluid (Graves and Williams,
1984). The origin of the substances isolated from plasma
has yet to be elucidated but the brain and the adrenal
glands are prime candidates. It has been demonstrated
that the natriuretic response to volume expansion was lost
following decapitation but not after adrenalectomy
(Kaloyanides, et al, 1977) but it has also been reported
that plasma levels of digoxin cross-reactivity decrease
following adrenalectomy in rats (Doris, 1988). These two
reports could be reconciled if the different activities
measured by different researchers were the properties of a
family of cardiac glycoside-like substances which possess
all or some of the properties which have been reported;
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natriuretic ability, inhibition of Na+K+ATPase, inhibition
of [^H]-ouabain binding, cross-reactivity with antibodies
to digoxin or ouabain. It is also possible that the
substance released from the adrenal could be under the
control of the hypothalamus.
SUMMARY OF WORK AND CONCLUSIONS
1. Plasma from normotensives and hypertensives was found
to contain methanol-soluble substances which both inhibited
Na+K+ATPase and cross-reacted with digoxin antibodies.
There was no difference in activities between the two
populations.
2. There was no correlation between the inhibition and the
cross-reactivity. This conclusion is supported by some
studies performed concurrently with this thesis.
3. At present, there is no concensus with regard to the
correlation between the activities. The reasons for this
include methodological differences which have already been
discussed.
4. The activity present in serum was separated on HPLC into
several fractions some of which showed both inhibitory
activity and cross-reactivity. Others possessed only one
activity. This is consistent with the majority opinion in
the literature.
5. The adrenal gland was found to contain considerable
activity which was also separated into several active
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fractions by HPLC. As with separation of serum, some
fractions had both inhibitory activity and cross-
reactivity, others had only one activity.
6. The adrenal fractions which showed both inhibitory
activity and cross-reactivity did not contain NEFA but the
activity may be due to a steroid-like substance since the
fractions were found to cross-react with digoxin, Cortisol
and corticosterone antibodies. The inhibitory capacity of
the fractions was stable to heat (80°C, lOmin) but
approximately half of the activity was lost following
incubation with trypsin.
7. The active fractions from the adrenal produced a marked
stimulation of steroid production. The results should be
interpreted with caution as the fractions may contain
steroid precursors. Further work is required on the




The following is a list of chemicals, enzymes, solvents and
radio-labelled compounds and their suppliers. All
reagents were of analytical grade.
Alpha Laboratories, 40 Parham Drive, Eastleigh, Hants., UK
Wako NEFA C test kit
Amersham International pic, White Lion Road, Amersham,
Bucks., UK
[ 125i]-Cortisol
BDH Ltd., Burnfield Avenue, Thornliebank, Glasgow, UK.
Ammonium acetate, citric acid monohydrate, disodium
hydrogen phosphate, gelatin, glacial acetic acid, glucose,
hydrochloric acid (conc.), magnesium sulphate, methanol,
potassium dihydrogen phosphate, sodium azide, sodium
chloride, sodium hydroxide, 2-amino-2-
(hydroxymethyl)propane-1,3-diol (Tris), 2-([2-hydroxy-l,1-
bis(hydroxymethyl)-ethyl]amino)ethanesulphonic acid (TES).
CMP(UK) Ltd., 12 Yeomans Park, Yeomans Way, Bournemouth, UK
[125i]-dig0xin
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Ciba Corning Diagnostics Ltd., Halstead, Essex, UK
IOC
[xz--'i ] -digoxin
Flow Laboratories, Woodcock Hill/ Harefield Road,
Rickmansworth, Herts., UK
Medium 199 (modified) with Earles's salts, with glutamine,
without bicarbonate.
ICN Biomedical Ltd., Free Press House, Castle Street, High
Wycombe, Bucks., UK
R .
Pentex bovine serum albumin, fraction V
Immunodiagnostics Ltd., Usworth Hall, Washington, Tyne &
Wear, UK
-IOC 1 o c
[I]-aldosterone and [ I]-corticosterone
Lome Diagnostics Ltd., Unit 11, Cratfield Road, Moreton
Hall Industrial Estate, Bury St.Edmunds, Suffolk, UK
Collagenase (type I)
NBL Ltd., Unit 11, South Nelson Industrial Estate,
Cramlington, Northumberland, UK
Earle's balanced salt solution
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Rathburn Chemicals Ltd., Walkerburn, Scotland, UK
HPLC grade solvents; acetonitrile (S grade), methanol,
water.
Scottish Antibody Production Unit (SAPU), Law Hospital,
Carluke, Scotland, UK
Sheep anti-digoxin antiserum, sheep anti-cortisol
antiserum, normal sheep serum, donkey anti-sheep IgG
precipitating serum.
Sigma Chemical Co. Ltd., Fancy Road, Poole, Dorset, UK.
Adenosine 5'-triphosphatase (dog kidney), adenosine 5'-
triphosphate (disodium salt, vanadium free), aldosterone,
ascorbic acid (free acid), ammonium molybdate tetrahydrate,
bovine serum albumin, charcoal (activated), ethylene
glycol-bis (/3-aminoethy lether) N,N,N',N', - tetraacetic acid
(EGTA), imidazole, L-lactic dehydrogenase, magnesium
chloride, -nicotinamide adenine dinucleotide (NADH,
reduced form), ouabain octahydrate, pepstatin A,
phenylmethylsulphonyl fluoride (PMSF), phosphoenolpyruvate
(tricyclohexylammonium salt), potassium chloride, potassium
phosphate, pyruvate kinase, sodium arsenite, sodium
chloride, trisodium citrate, trichloroacetic acid,
tris(hydroxymethyl)aminomethane (Tris), N-
tris(hydroxymethyl)methyl 2-aminomethane sulphonic acid
(TES), trypsin, trypsin inhibitor (soya bean).
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APPENDIX II
COMPOSITION OF BUFFERS AND REAGENTS
All buffers and reagents were prepared using distilled
water and stored at 4°C.
REAGENTS FOR COLORIMETRIC Na+K+ATPase ASSAY
Imidazole buffer, lOmM, pH 7.4
Imidazole (lOmM), sodium chloride (lOOmM), potassium
chloride (5mM), magnesium chloride (12mM), EGTA (5mM) - pH
to 7.8 with conc. sodium hydroxide.
Arsenite-citrate reagent
To lOg trisodium citrate and lOg of sodium arsenite dissolved
in 400ml distilled water, add 10ml glacial acetic acid and
make up to final volume of 500ml.
REAGENTS FOR ENZYME-LINKED Na+K+ATPase ASSAY
The Cobas FARA adds diluent (distilled water) to the cuvettes
in addition to sample and reagent so it is necessary to
allow for this dilution when making up reagents.
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Add EGTA to distilled water (approximately one tenth
to one fifth of the final volume) pH to approximately 7
with concentrated sodium hydroxide. When dissolved add
this to a solution containing the other salts. This
should have a pH of 7.8 at room temperature (20°C) which











Lactate dehyrogenase 17 U/ml








TTS and assay cocktail (minus enzymes and NADH) can be
prepared and stored at 4°C for one month. Solutions
containing NADH and enzymes must be prepared and used on
the same day, these cannot be stored.
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OTHER BUFFERS
Ammonium acetate, 20mM, pH 7.4
Make up a 20mM solution of ammonium acetate and pH to 7.4
using ammonia solution.
Homogenising buffer, 50mM, pH 7.4 (4°C)
Combine Tris (50mM), EGTA (ImM), PMSF (0.2mM), pepstatin A
(0.05pg/l) and pH to 7 with conc.HCl. First dissolve PMSF
in a small volume (approx. 3-5ml/l buffer) of ethanol and
add to a solution containing Tris and EGTA. Add pepstatin A
after the buffer has been brought to pH 7 (equivalent to pH
7.4 at 4°C).
Tris-buffered saline, 50mM, pH 7.4 (37°C)
Tris (50mM) and sodium chloride (140mM), pH to 7.8 (20°C)
with conc.HCl. This will have a pH of 7.4 at 37°C.
DIGOXIN RIA REAGENTS
Phosphate buffer, 50mM, pH 7.2
Prepare 50mM phosphate buffer by adding 50mM potassium
dihydrogen phosphate to 50mM disodium hydrogen phosphate to
give a pH of 7.2. To 11 of this add 5.0g BSA, l.Og sodium
azide and 58g sodium chloride.
Pre-precipitated antibody reagent
In a universal container combine 11ml phosphate buffer,
50pl sheep anti-digoxin antiserum (SAPU), 940|il normal
sheep serum (SAPU), 12ml donkey anti-sheep IgG (SAPU).
Mix well and leave overnight at 4°C. Centrifuge (200 x g,
5min) and decant supernatant. Resuspend precipitate in
190
20ml phosphate buffer and centrifuge (200 x g, 5min) .
Decant supernatant and resuspend precipitate in 20ml
phosphate buffer. For use in digoxin RIA, add contents of
universal to 160ml phosphate buffer.
CORTISOL RIA REAGENTS
Citrate buffer, 0.1M, pH 4
For 0.1M citrate buffer, pH 4, dissolve 24.8g citric acid
(monohydrate) and 24.lg trisodium citrate (dihydrate) in
distilled water and make up to 21. Dissolve 4g gelatin in
approx. 200ml buffer with gentle heat and stirring. Allow
to cool, add back to the rest of the buffer (final
gelatin concentration = 0.2%) and add 0.13g sodium azide.
Pre-precipitated antibody reagent
In a universal container combine 650jul sheep anti-cortisol
antiserum (SAPU), 530pl normal sheep serum (SAPU), 15ml
donkey anti-sheep IgG (SAPU), 10ml citrate buffer. Mix
well and store overnight at 4°C. Centrifuge (200 x g,
5min) and decant supernatant. Resuspend precipitate in
20ml citrate buffer and centrifuge (200 x g, 5min).
Decant supernatant and resuspend precipitate in 20ml
citrate buffer. For use in Cortisol RIA, dilute to final
volume of 500ml.
REAGENTS FOR CORTICOSTERONE RIA AND ALDOSTERONE RIA
Phosphate buffer, 50mM, pH7.4
Prepare 50mM phosphate buffer, pH7.4, from disodium hydrogen
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phosphate dodecahydrate (14.5g/l) and potassium
dihydrogen phosphate (1.29g/l).
Charcoal suspension
Dissolve gelatin (0.06%) in phosphate buffer using gentle
heat and stirring. Once dissolved, cool and add dextran
(0.06%) and charcoal (0.6%).
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APPENDIX III
PREPARATION OF CYTOSOL FROM BOVINE ADRENAL CORTEX
Adrenal glands were transported to the laboratory on ice
and kept on ice between dissection and homogenisation and
while waiting to be centrifuged.
Procedure
Remove fat from individual glands
V
Cut gland in half and scrape away medulla
V
Roughly chop glands and homogenise in 3 volumes of
homogenising buffer (Appendix II)
V
Centrifuge homogenate (15 000 x g, lh, 4°C)
V
Filter supernatant through gauze and centrifuge
(100 000 x g, 45min, 4°C)
V





The following is a list of the abbreviations used in this
thesis.
A34Q absorbance value at 340nm
A70q absorbance value at 700nm
All angiotensin II
ACTH adrenocorticotrophic hormone
ASF aldosterone stimulating factor
ATP adenosine 5'-triphosphate
ATPase adenosine 5'-triphosphatase
AV3V anteroventral third ventricle
BSA bovine serum albumin
C^g octadecylsilane
CRF chronic renal failure
CSF cerebrospinal fluid
CV coefficient of variation
DLIR digoxin-like immunoreactivity
DOCA deoxycorticosterone acetate
EBS Earle's balanced salt solution
EHT essential hypertension
FAB mass spec. fast atom bombardment mass spectrometry
HPLC high performance liquid chromatography
IHA idiopathic hyperaldosteronism
Ml 99 medium 199
MAP mean arterial blood pressure
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MRC Medical Research Council
Na+K+ATPase sodium potassium ATPase
NADH /^-nicotinamide adenine dinucleotide
(reduced)
NAD+ /^-nicotinamide adenine dinucleotide
(oxidised)
NAF non-adsorbed filtrate
NEFA non-esterified fatty acids
RIA radioimmunoassay
SHR spontaneously hypertensive rats
TBS tris-buffered saline
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Improvements in precision and detection limit in a
sensitive phosphatemicroassay
Karen Traill and Joseph E Roulston
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Abstract
A sensitivemirruasuy for phosphate showed imprecision both on a
phosphate standard curve and on a ouabain inhibition curve. This
imprecision could lie due to formation of a phosphate-independent
complex when arsenite-citrale reagent addition is dclajed, or to
incomplete formation of the desired phosphouiot)hdale complex,
caused by inadequate mixing. These p*issiliililies were investigated
by delayed addition of arsrnile*citratc reagent and by mixing
reagents after the final addition (terminal mixing) or mixing after
each reagent was added (sequential mixing).
It was concluded that sequential mixing both improves precision
and decreases effective detection limit.
Introduction
Micro-coloriinctric assays for inorganic phosphate, dependent on
live formation of a phosphoinoiylxlate complex, have been
available since (he early I954K. Measurement of inorganic
l>hiisphaie by this technique involves precipitation of the
phosphomoiybdate with a basic dye at a low pi I. then redissolving
it in acettme and measuring tltc ahsorbance. Alternatively, the
alisorbance of (lie phosphomoiybdatc complex can be measured
after treatment with a reducing agent.
'lite first basic dye to Ik* used in a micro-assay for phosphate was
safratun 111. By replacing salranin with malachite green, and using
detergent to prevent the dye-phosphomolybdate complex from
|Keci|)iiating out. Itaya and Ui |2| were able to determine
inorganic phosphate concentrations as low as I nmol.ini
iuithcr improvements on this assay |3| made it |K»sible to
iiK'asure inorganic phosphate in the tl.2-16 nmol.ml"' range.
Increasing at>sorbancc of samples and blanks with lime, was
noted hy lain/ctla er nl |4). Tins problem was overcome, while
retaining sensitivity, by nnxlilymg a quenching procedure
OK m&mi! /ml|
dcvclo|K*d for use in an assay where phosphonuilylKlatc is
reduced |5|.
An assay, using ihodammc B to precipitate phosphomoly-
bdate. was refuted recently |h| which covers the same range as
the assay of Laiuclla ilut. I fowever. at phosphate concentrations
greater than Inntol.mi'1 the ahsorhancc was greater than I: for
linear measurements, it is advisable to keep the absorbauce
readings less than I. Also, rhodauiine B is sus|K*ctcd of being a
carcinogen and its use therefore requires extra safety precautious.
A variety of compounds have been used to reduce
phosphomolybdate. These include ferrous sulphate |7|. used in
one of the earliest microphosphate assays, hydroquinone |8|. 1.2.
4-amiiionaphthoisulphonie acid |9| and ascorbic acid |5.1U|.
Triton X- MM) has been used in place of reducing agents (111 but its
major drawback is that the ilclay between addition of ammonium
moiybdatc and measurement of absorhance must always Ik*
identical.
The phosphate released by Na*K* ATPasc can be measured in
several ways. In NAD-linked assays, hydrolysis of ATP is linked
to oxidation of NADil through pyruvate kinase and lactate
dehydrogenase 112|. This type of assay is usclui for studying the
kinetics of ATPase but is unnecessarily complicated for studies
where the kinetics are not of primary interest. Use of
radiol.ilK*llcd ATP is a direct but expensive way to assay ATPase
activity |13|; measured as the amount of '"P released from ATP
labelled on the '/-position. Coloriinetric assays liavc the virtues of
being relatively inexpensive and direct. The dyc-hiiuiing methods
are sensitive IhiI have a limited range and require rigorous
cleaning of glavswarc to remove inorganic phosphate.
Of the methods employing reducing agents, the assay of
Haginski and Zak |>| is simple to perform, uses relatively low-cost
reagents that are easy to prepare and store, and the colour
produced is stable for 24 h. In this assay, ascorbic acid is used to
reduce pliosphomolyhdatc and free molytxlaic iscomplcxcd with
arscnitc-citratc reagent mi that any inorganic phosphate released
alter (he colour reagents have been added will not affect the
results. This technique has been nuxJilied for use in low
I
Figure I Ileft) Plot of absorb.ince at 700 run as a function of dose of
phosphate standard the hguic demonstrates the improved precision
when reagents are sequentially nuned
• • Standarddose rest>onse (sequentialminingi
G C' Standarddose-'espouse (terminalmumyj
A A Precisionprofile (sequentialmining!
A A Precisionprofile i terminalmixing)
Figure 2 Dose response curves lot ouabain inhibition of No' K' A TPase.
showing improved precision and sensitivity when reagents are
sequentially mined
• • Standarddose responses (sequentialminriyj
G C Standarddose-'csnonscs (tcrmin.ilmining!
A ▲ Precision profile (sequentialmmng)
A A Precision prohle (terminalmining/
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protein-content assays (141 and in assays of microsomal ATPusc
preparations (IS). Despite (he stability of the colour produced,
considerable imprecision in early experiments with this method
was noted. There were several possible explanations for this lack
of precision, and (his paper describes their investigation.
Materials and methods
Reagents
All reagents were of analytical grade and obtained from Sigma
Chemical Co Ltd. Poole. Dorset. UK.
Phosphate standards (1-88 nmol/ml) were made up by serial
dilution of stock standard (0.5 mol/l) with 0.61 M trichloroacetic
acid (TCA) and stored at 4*C for eight weeks.
Ascorbic acid (0.57 M) and ammonium moiybdatc (H.I mM)
were made up in distilled water. Arsenile-citrate reagent
contained 77 mmol of sodium-m-arscnitc, 34 mmol of trisodium
citrate and 10 ml glacial acetic acid made up to a final volume of
500 ml with distilled water.
Imidazole buffer (10 mM). containing sodium chloride (Ilk)
mM). potassium chloride (5 mM). magnesium chloride (6<nM)
and ethylene glycol-bis (B amino ethyl ether) N.N.N'.N'-
tetraacetic acid (0.5 mM) was adjusted to pi I 7.H using sodium
hydroxide (0.1 M).
Adenosine 5'-triphosphalase (ATPase. 0.75 units/ml. from
porcine cerebral cortex) was made up in imidazole buffer. One
unit of ATPasc activity liberates one pmol inorganic phosphate
from ATP per minute at 37°C. at pi I 7.H and in the presence of
Nil*, K* and Mg;*.
Ouabain standards (0.008-1 nmol/ml) were made up by serial
dilution of slock standard (2 mM) with imidazole buffer and
stored at 4°C for eight weeks.
All slock standards were stored at -2(PC.
Phosphate essay
The assay was based on that of Raginski and Zak |4|. Sample or
phosphate standard (50 pi) was added to I ml TCA (0.61 M),
mixed and left to stand at room temperature for 10 min. After
centritugaiion (2H00 g. 3 min. 4°C), 500 pi oi the supernatant was
added to 100 pi of ascorbic acid. To this, 250 p| ammonium
inoiybdate were added followed by 500 pi arsenite-citrale
reagent. After 15 min the absorbancc was read at 700 nm in a Pye
Unicum SI'S-100 UV/Vis spectrophotometer. Tubes were shaken
either alter each reagent was added (sequential mixing) or after
the final reagent has been added (terminal mixing).
Phosphate generation
100 pi ATP. 750 pi imidazole buffer and 50 pi ouahain standard or
bufler were prc-incubaled fur 10 min at 37°(\ The reaction was
stalled by adding 100 pi ATPase und stopped after 60 mm at 37V
by aiklition of I ml icc-cold TCA (O.bl M). A sample (50 pi) wus
taken for phosphate assay.
Results
Figure I compares the phosphate standard curves and the
precision profile (CV) obtained under conditions of sequential
and of terminal mixing of reagents. The equations for these curves
are y«0.0l3 * 0.0IM x and y»0.085 + 0.021 x. respectively. The
slope of the curve was not altered significantly by sequential
mixing of reagents, but precision at each point was considerably
improved as compared with the precision observed when terminal
mixing was adopted. The mean coefficient of variation (CV)
decreased from 18.2% to 4.2% (pd).OUI); the precision profiles
show that the CV on sequential mixing came closer to zero than
the CV obtained when the reagents were mixed terminally.
Inicrassay precision of sequentially mixed assays was measured
by triplicate assay of a 44 pmol/l phosphate standard on ten
different days over a period of six weeks. The interassay CV was
3.3111.36%.
figure 2 compares the precision obtained with the phosphate
assay, using sequential and terminal mixing, iii a ouabain
inhibition study. If the detection limit is defined as the
concentration of ouabain which will depress phosphate
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production by one standard deviation. Figure 2 shows that with
sequential mixing the detection limit was improved from 7 x 10""
mol/l to 4 x 10" mol/l (p<0.(X)l). This was accompanied by an
improvement in mean CV from 28.5 to 5.2% (p«0.(X)l).
It was found that a phosphate-independent complex, which
absorbs at 700 nm. was formed when addition of arscnitc-citratc
reagent was delayed. In sequentially mixed assays the absorbance
rise due to formation of the phosphate-independent complex did
not become significant until the addition of the arsenite-citrate
reagent was delayed by 7.5 min. The effect of delayed
arsenite-citrate reagent addition was enhanced in phosphate
assays in which the reagents were terminally mixed (Table 1).
Discussion
Sequential mixing of phosphate assay reagents produced a
marked improvement in precision. This was observed both on a
phosphate standard curve (Figure 1) and on a ouabain inhibition
curve (Figure 2).
The intercept of the phosphate standard curve decreased as
precision improved. The intercept could be due to formation of a
phosphate-independent complex, but the high degree of
imprecision on the terminally-mixed standard curve could also be
responsible for the increased intercept.
Incomplete formation of the phosphomoiybdate complex, due
to incomplete mixing, is more likely to have been responsible for
imprecision. Delayed addition of arsenite-citrate reagent
produced a significant increase in absorbance at 2.5 min (p«0.00l)
in terminally mixed assays, but did not produce a significant
increase until 7.5 min (p«0.05) in sequentially mixed assays. In
routine practice, the delay before addition of arsenite-citrate
reagent was never longer than 5 min.
Improvement in precision resulted in a considerable
improvement in the lower limit of detection of ouabain inhibition
of Na * K* ATPasc. This increases the usefulness of the assay as a
means of detecting the low levels of an endogenous, ouabain-like
inhibition that is believed to be responsible for (he pathogenesis
and maintenance of essential hypertension |16|. It is important
that the methods used to study this inhibition should be direct, as
otherwise the interpretation of these experiments becomes very
complex.
Microphosphate assays have a wide variety of potential
applications. This assay could also be of value in. for example, the
study of myosin ATPase (17| or Na * K * ATPase activity of Golgi
membranes |IH|.
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Table I. Increase in ubstirbancr us u function of deluved addition of
arsenile-cilrute reagent in sequentially and terminally nu ted phosphate
Ahsorhanec at 7im nm as a percentage of
lime zero value
Delay lime Sequentially Terminally
(min) mixed assays mixed assays
(1 Itll Kill
2.5 •M.5 133.1 ♦
5 lilt 7 133.2 +
7.5 103.5* 150.2+
III I02.fi* 141.3 +
15 III7.5+ 142.3 +
21» 113.7 + 161.2 +
*p<lUl5 with icspect to time zero value
+ p<ll.iail with respect to time zero value
Microcomputer interfacing: an asynchronous serial
communications interface
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Abstract
The design and operating details are presented for u low-cost
asynchronous serial ctiiniuuiiiealions iulcrfaee for use willi Apple
II tnieroeuiiipulers. Mils interface eutt Ik- operated in KS 232C or
20 inA currciil-loop inmles at switch selectable hand rates. The
device permits seriul tlalu transfer between eonipulers or Itciwccn
lite host cmiiputer ami suitable lalroralnry instrumentation.
Introduction
Rapid advances in semiconductor technology have provided
laboratory instrumentation manufacturers with a wealth of digital
processor devices which can lxa included in their products. Almost
all modern instruments incorporate some form of niicmprtx'cssor
unit atul/or some means of interfacing the instrument to a host
computer. One common interface is (he F.IA KS 232C. a
hit-serial data transmission standard suitable for low-cost data
transfer at relatively low transmission rates. Whilst the full
US 232C standard specifies a 25-piu connector lictwccn the
computer and the peripheral device, only three interconnecting
lines arc often required. \-i; transmit data, receive data and a
ground line.
A similar interface is (he 20 mA current-loop system. This is
used in many of the older mechanical typewriters and for
applications requiring serial data transmission over extended
distances.
Described here is a simple circuit hoard which performs us an
asynchronous serial communications inteifaee which is directly
compatible with the Apple II and III: micrix'omputer systems and
is switch-selectahic for operation in RS 232C or 20 mA
currcnt-loop modes.
Circuit details
The circuit diagram is illustrated in Figure I. The interface is
designed around the 6850 usyitciiioiious communications
interface adaptor (AC'IA). The AOA includes features for
formatting and controlling such peripheral devices as modems,
CRT terminals and teletype printer/readers. Data transfer
between the ACIA and (he microprocessor is via eight
bi-directional lines that interface directly with the
microcomputer's data bus. The direction of data How (ic receive
or transmit) is controlled by the status of the RHAD/WRITE line
from the microcomputer (pin IK of the Apple edge connector).
The primary function of the ACIA is to convert parallel data from
the microcomputer bus to serial format and conversely, to convert
serial data from the external device to parallel format. Options,
such as word length, stop bits and partly checking status are
established by writing the appropriate hit pattern into the AClA's
control register.
The circuit also contains a baud-rate generator and selector
switches and the necessary line-driver/receiver components to
achieve the 2 12 V pulses normally used in the RS 232C standard.
It can be seen from Figure I that the transmit ^ind receive
baud-rate lines arc connected together, and arc switch selectable
to provide the usual data transfer rates in the range 50 baud to
baud. The input/output of the ACIA can he switched from
the RS 232C* line driver/receiver units to the receiver and
transmitter of the 20 mA current-loop system.
Operation and software
The Apple II and HE microcomputers arc constructed with edge
connector slots for peripheral hoard expansion. The serial
communications interface described here is directly compatible
with this arrangement and requires no external power supply unit.
Figure 2 illustrates a typical 'auto-loopback' configuration
using a three-wire serial link between the host Apple computer
and a peripheral device. Such an arrangement has been discussed
by l.esca and Zaks |l| and used for the control of an infra-red
spectrometer and for communications between microcomputers
and other dicital systems, including inter-computer links |2 and
y\
.
Table I provides a simple machine code routine which allows
the Apple microcomputer to serve as a 'dumb' terminal for
general purpose interfacing, say. to a second computer system.
On calling ihis routing, a master reset of the ACIA is performed
•U»d the AC'IA is then set for a data standard of eight data hits, no
parity cheek and one stop hit. Further details of setting the AC'IA
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Direct demonstration of an inhibitor of sodium,
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(Na+,K+-ATPase) in plasma from normotensive
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Summary
An endogenous inhibitor of Na"\K+-ATPase was extracted from human plasma
and sera and concentrated by a novel reverse-phase octadecylsilane chromatography
method. The active extracts (eluates) were dried and reconstituted in the minimum
volume of the non-adsorbed fraction of the plasma from which they had been
derived. Reconstituted eluates, non-adsorbed plasma fractions and native plasma
samples were then tested for their ability to inhibit phosphate production in
standard Na+,K+-ATPase incubation mixtures. In a pilot study 31 samples of
pooled normal human sera were assayed. The eluates gave a significantly lower
production of phosphate than the non-adsorbed fractions or the native sera (« = 31,
p < 0.0025). Further concentration of the eluates by repeated chromatography
increased the inhibitory power of the eluate proportional to the concentration
achieved, as quantified by ouabain dose-equivalents.
In clinical studies, samples from 12 normotensive subjects and from 12 untreated
patients with essential hypertension were tested. Significant inhibition of the ATPase
by the eluates, as compared to the corresponding non-adsorbed fractions was seen
for samples from both normotensive (p < 0.05) and hypertensive (p < 0.05) sub¬
jects. There was no significant difference in incidence or degree of inhibition
between the normotensive and hypertensive groups. This study provides direct
evidence for the presence of an endogenous inhibitor of Na+,K+-ATPase in human
plasma.
* To whom correspondence should be addressed.
0009-8981/86/S03.50 © 1986 Elsevier Science Publishers B.V. (Biomedical Division)
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Introduction
High blood pressure is a common condition associated with increased risk of
myocardial infarction, cerebrovascular accident (stroke) and renal damage. In over
90% of cases the cause of the high blood pressure is not known ('essential'
hypertension), although it may be amenable to pharmacological control with con¬
comitant decrease in the risk of organ damage [1-4],
It has been proposed by de Wardener and MacGregor [5] that the pathogenesis
and maintenance of high blood pressure is due to an endogenous inhibitor of
sodium transport ('natriuretic factor') secreted in response to dietary sodium-load¬
ing in people genetically predisposed to high blood pressure. This inhibitor is
believed to act by blocking the ouabain-sensitive component of Na+,K+-ATPase;
one result of this is increased natriuresis by the kidney. Other side-effects of this
inhibitor's action are thought to be increases in intracellular sodium and calcium
which, in smooth muscle cells of the blood vessels, lead to an increase in peripheral
resistance and, thereby, blood pressure.
Ideally the demonstration of the presence of an inhibitor of Na+,K+-ATPase
should attempt to address the following points: measurement of inhibition of
phosphate production by the ATPase should be direct, the plasma must be extracted
with the minimum of insult to its native components, the procedure should allow
investigation of a large number of samples in a single assay, utilise samples
obtainable from routine clinical practice, and finally the extract should be sus¬
pended in a matrix as close to human plasma as possible to prevent unnecessary
artefacts. In this study we considered these factors by using a new extraction
procedure to concentrate the inhibitor which was then dried and reconstituted in a
minimum volume of the non-adsorbed plasma from which it had been extracted. In
the pilot study each extract was assayed in parallel with the native serum and
non-adsorbed fraction as internal controls; in the clinical study non-adsorbed
plasma fractions were used as internal controls. Phosphate production by ATPase
was measured directly. We report findings of this pilot study and clinical study
using age-matched normotensive and untreated hypertensive subjects.
Material and methods
Reagents
ATP: Disodium adenosine triphosphate (calcium and vanadium free) prepared
from equine muscle (Sigma Chemical Co. Ltd., Poole, Dorset, UK) was dissolved in
imidazole buffer (vide infra), the pH adjusted to 7.8 with 0.1 mol/1 sodium
hydroxide, and stored at — 20°C in a concentration of 100 mmol/1.
Na+,K+-ATPase: Adenosine 5'-triphosphatase (ouabain-sensitive) obtained from
porcine cerebral cortex, (Sigma Chemical Co. Ltd.) was stored at — 20°C in
imidazole buffer (0.75 U/ml). One unit liberated one micromole of inorganic
phosphate from ATP per min at 37 °C, at pH 7.8 in the presence of sodium,
potassium and magnesium ions and excess ATP.
Imidazole buffer: This was 10 mmol/1 and contained 100 mmol of sodium
chloride, 5 mmol potassium chloride, 6 mmol magnesium chloride (as hexahydrate)
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and 0.5 mmol ethylene-glycol-bis(jS-aminoethylether) N, N,N', A'-tetraacetic acid
(EGTA) per litre. The pH was adjusted to 7.8 with 0.1 mol/1 sodium hydroxide.
Arsenite-citrate reagent: This contained 17 mmol sodium-m-arsenite, 34 mmol
trisodium citrate and 10 ml glacial acetic acid made up to a final volume of 500 ml
with distilled water.
Standards'. Working phosphate standards were made up by serial dilution of a 0.5
mol/1 primary phosphate standard in 0.61 mol/1 trichloroacetic acid (TCA). The
working standards were stable for up to 8 weeks at 4°C and covered a range from 1
to 88 jumol/1. The primary standard was stored in aliquots at — 20°C.
Working ouabain standards were made over a range of 8 pmol/ml to 1 nmol/ml
by dilution in imidazole buffer of a primary (2 /rmol/ml) standard. The primary
standard was stored in aliquots at — 20 °C the working standards were stored for up
to 8 weeks at 4°C.
All reagents were of analytical grade and obtained from the Sigma Chemical Co.
Ltd., St. Louis, MO, USA.
Phosphate assay
Phosphate was measured by a technique based upon that of Baginski and Zak [6],
50 p 1 of sample or standard were added to 1 ml of 0.61 mol/1 TCA, mixed
thoroughly and allowed to stand at room temperature for 10 min, and then
centrifuged at 2800 X g at 40°C for 3 min. 500 jul supernatant were then added to
100 jul 0.57 mol/1 ascorbic acid and vortex mixed. To this mixture was added 250 ju.1
of 8.1 mmol/I ammonium molybdate and the tubes re-mixed by vortex. Finally, 500
p\ arsenite-citrate reagent were added, the contents mixed and allowed to stabilise at
room temperature for 15 min. The solutions were transferred to microcuvettes (1 ml
capacity) and the absorbance at 700 nm recorded on a Pye-Unicam SP8-100
spectrophotometer, using distilled water as blank. Thorough mixing of reagents at
each stage is critical to precision [7].
A TPase incubation
750 pi imidazole buffer, 100 /rl ATP (50 /xmol) and 50 ;iil sample or buffer were
preincubated for 10 min at 37°C before the reaction was started by addition of 100
jul ATPase (0.075 U). The reaction was allowed to proceed for 1 h at 37 °C and was
then terminated by addition of 1 ml of 0.61 mol/1 ice-cold TCA. 50 jul portions of
the incubate were then removed for phosphate assay. All assays were performed in
triplicate and blanks for substrate, enzyme, sample and incubation time routinely
included to correct for endogenous phosphate and enzyme-independent breakdown
of ATP.
A standard curve, using known concentrations of ouabain instead of plasma
extract samples, was constructed in order to quantify any inhibition by the extracts
in terms of ouabain dose-equivalents.
Patients and samples
For the pilot study 31 X 10 ml portions of a pooled human serum which had been
stored at — 20°C were used. For the clinical study 10 ml blood samples were taken
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from the antecubital vein of 12 untreated, newly diagnosed essential hypertensive
patients, defined by the World Health Organisation gradings as I or II (MAP
137.3 + 6.4 mmHg), and 12 age-matched normotensive volunteers (MAP 96.4 + 2.0
mmHg). Mean arterial blood pressure (MAP) was defined as diastolic blood
pressure plus one third of the pulse (systolic-diastolic) pressure. Figures are
given + one standard error of the mean (sem). The blood was placed in lithium-
heparin tubes, centrifuged and the plasma stored at — 20 °C until required. Re-
centrifugation upon thawing was sometimes necessary to remove precipitates in¬
duced by freezing.
Extraction procedures
The extracts were prepared from the serum or plasma by reverse-phase octade-
cylsilane column chromatography (Sep-pak C18, Waters Ltd., Cheshire). The col¬
umns were primed with 5 ml of methanol followed by 5 ml of distilled water. The
serum or plasma samples (2.5-10 ml as available) were applied to the columns by
hand pressure through a nylon 10 ml syringe. The liquid which passed through the
column (the non-adsorbed fraction) was retained, as was a sample of the native
serum in the pilot study. The column was then washed with 5 ml distilled water and
adsorbed material (the eluate) removed from the column with 5 ml of methanol. The
eluate was collected in a glass quickfit tube and reduced to dryness under a stream
of oxygen-free nitrogen in a water bath at 50 °C.
The eluate was reconstituted by adding a minimum volume (350 /xl) of its
corresponding non-adsorbed fraction and vortex-mixing the tube thoroughly.
Eluates, non-adsorbed fractions and native sera were then tested for the ability to
inhibit phosphate production in the ATPase incubates. Results from the pilot study
indicated that assay of native plasma gave virtually identical results to assay of
non-adsorbed fractions. Therefore, for the clinical plasma samples, where volume
was critical, the whole sample was applied to the column for extraction.
Statistical methods
Differences between phosphate production in non-adsorbed fractions and eluates
were assessed by Student's t-tests (paired or unpaired, as appropriate). Probabilities
> 0.5 were regarded as not statistically significant. Standard curves were assessed by
estimation of the coefficient of variation of the response variable of each standard
point ('precision profile'), and linear regression analysis where appropriate.
Results
The phosphate standard curve showed a mean coefficient of variation (CV) of 1%
for phosphate concentrations > 5 nmol/ml. Below this precision decreases markedly.
In practice, the range of the line used for interpolation was between 15 and 40
nmol/ml. Linear regression analysis with phosphate concentration the independent
variable yielded y = 0.013 + 0.019x, r = 1.000, p < 0.001, sy ■ x = 0.008. Interassay
precision was assessed by repeated assay of a 44 nmol/ml phosphate standard on 10
different days. The CV was 3.3%. Phosphate production by the ATPase incubates
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Fig. 1. Ouabain inhibition of phosphate production. Example of a standard curve (•) and precision
profile (a).
was linear with respect to time, up to at least 100 minutes (y = 0.08 + 0.007.x,
r = 0.995, p < 0.001, jy • x = 0.024). The CV of the ATPase incubation procedure as
measured on the ouabain inhibition curve was 5.2% (Fig. 1). The detection limit,
defined as the dose of ouabain required to reduce the production of phosphate
(A700) by one standard deviation, was 4 X 10 ~ 9 mol/1.
Since blood samples were collected into lithium-heparinate and the lithium ions





























Fig. 3. Recovery of ouabain as a function of methanol volume.
phate generation was investigated. Lithium concentration less than 10 mmol/1 had
no significant effect, above this concentration slight activation occurs (Fig. 2). When
samples are subjected to chromatography virtually all Li+ remains in the non-
adsorbed fraction (mean concentration 0.1 mmol/1). Any small traces remaining on
the columns, even if totally eluted in methanol subsequently and concentrated by
the procedure described, could not increase Li+ concentration to greater than 0.35
mol/1 in the eluate.
The extraction procedure was tested using plasma samples to which known
concentrations of ouabain had been added. These samples were then used as models
to assess the adsorption, elution, recovery and reproducibility of the technique. In
our hands, a 10 nmol dose of ouabain was all retained by the column whether
contained in 2.5, 5 or 10 ml of plasma. No ouabain was lost in the water wash.
Recovery of ouabain in the methanolic eluate was around 90% using methanol
volumes of 1-5 ml but decreased markedly at higher volumes (Fig. 3).
In the pilot study, comparison of the phosphate production by the untreated sera
and the non-adsorbed fractions showed no significant difference (unpaired /-test,
n = 31, not significant). Comparison of non-adsorbed fractions with eluates, how¬
ever, showed a statistically significant decrease in phosphate production by the
ATPase incubates which contained portions of eluate. (n = 31, p < 0.0025, mean
ouabain dose-equivalent 7.8 X 10~9 mol/1 of serum). Further concentration of the
eluate remnants by a repeated chromatography step on a fresh column (concentra¬
tion factor achieved = 11.8) produced, on elution with methanol, a fraction contain¬
ing 9.0x10"8 mol/1 ouabain dose-equivalent which compares closely with a
predicted value of 9.2 X 10"8 mol/1. The non-adsorbed fraction from this second
chromatography step showed no inhibitory capacity.
In the study with samples from normotensive volunteers and untreated patients
with essential hypertension there were falls in phosphate production in ATPase
incubates containing eluates of these plasmas which, despite the small number of
samples, achieved statistical significance (paired /-test) with respect to non-adsorbed
fractions in both normals (n = 12, p < 0.05) and hypertensives {n = 12, p < 0.05).
The results are summarised in Table I. As individual sample sizes were smaller, it
was not possible to concentrate the eluates to the same extent as the pilot study and
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TABLE I
Inhibition of phosphate production by plasma eluates
The results show that the enzyme activity is significantly reduced in plasma eluates by comparison with
non-adsorbed fractions.




Native sera 1 2.92X10"5 55 ONOXV
Non-adsorbed fractions 31 2.96 XlO"5 56 <4 XlO"9
Eluates 31 2.72X10"5 51 * 7.8 X10"9
Re-concentrated eluates 1 1.93 X 10~5 36 9.0 x 10"8
(b) Normotensives
Non-adsorbed fractions 12 2.63 XlO"5 50 OsOXV
Eluates 12 2.50 x io~5** 47 ** <4 XlO"9
(c) Hypertensives
Non-adsorbed fractions 12 3.06 XlO"5 58 A -P*. X o sC




p < 0.0025 with respect to non-adsorbed fractions (unpaired r-tests).
**
p < 0.05 with respect to non-adsorbed fractions (paired r-tests).
leave sufficient eluate after assay for re-extraction. When the normotensives and
hypertensives were compared with each other (independent r-test) no significant
difference in incidence or degree of inhibition of phosphate production by the
presence of plasma eluate was demonstrable (n = 12, not significant). Of the 24
sample eluates, 3 achieved greater than 10% inhibition, 6 greater than 5%; equiv¬
alent to ouabain dose-equivalents of 14 nmol/1 and 7.2 nmol/1 respectively. There
was no significant correlation (linear regression analysis) between mean arterial
blood pressure and degree of inhibition for either group.
Discussion
Although the phosphate assay worked extremely reliably with a CV of 1%, the
ATPase incubation was not ideal because the sensitivity of the method (limit of
detectability) was still in the jumol/1 range. Thus quantification of the inhibition
was subject to considerable imprecision as the change in the response variable at
low levels of inhibition is small. The inhibition curves were, however, reproducible
and precise and further optimisation may be possible by reduction of ATPase
concentration in the incubates. The sample preparation, although not able to
concentrate manageable sample sizes sufficiently to overcome the sensitivity prob¬
lem of the ouabain inhibition curve, did have certain advantages over other
techniques. The method enabled a marked degree of concentration (10-fold) with
minimal insult to the native plasma or sera and also provided, by means of the
non-adsorbed plasma fractions, a matrix for reconstitution which was extremely
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close to the original medium. Furthermore, the paired nature of the analysis (eluate
versus non-adsorbed fraction) gave a valuable internal control against artefacts,
such as matrix effects reported in digoxin immunoassays, and variations in ion
concentrations which may affect Na+,K+-ATPase activity. The use of blood sam¬
ples collected into tubes containing lithium-heparinate appears justified (Fig. 2), as
the Li+ ion cannot be selectively concentrated by this chromatography method to a
point where it can influence Na+,K+-ATPase activity [8]. The use of ouabain-treated
plasma as a model to test the extraction procedure indicates that adsorption and
elution are highly efficient over a wide range of concentrations and elution volumes.
This data does presuppose, however, that the behaviour of ouabain is a satisfactory
model for extraction of the endogenous inhibitor. Previous work in this field
indicates that the Na+,KT-ATPase inhibitor does possess certain ouabain-like
properties [9,10], Similarity of function in terms of ATPase inhibition is not direct
evidence for structural homology, but, in the absence of detailed information on the
structure of the endogenous inhibitor, it is the closest approximation available. The
fall in apparent recovery with large eluant volumes of methanol appears paradoxi¬
cal, but is most likely to be due to a failure to reconstitute completely the eluate in a
small volume of the non-adsorbed fraction, as it must be assumed some eluate dries
on the sides of the tube before the evaporation process is completed.
The data from the pilot study provided good preliminary evidence for there being
an inhibitor of Na+,K+-ATPase present which was concentrated by the chromato¬
graphy technique. Our findings are consistent with those reported earlier using
analogous techniques [11,12]. The data also showed that the non-adsorbed fractions
were good internal controls and identical to the native sera in their behaviour in the
assay. The further concentration step produced an extract with increased inhibitory
capacity to a level directly proportional to the increase in concentration factor. This
is evidence for the inhibition being due to a stoichiometric reaction of the Na+,K+-
ATPase with a specific inhibitor rather than a non-specific effect due to an artefact
of the extraction procedure.
Using the extraction technique described in this paper we have concentrated
bovine serum, plasma from patients with poly-cythaemia, and plasma pooled from
normotensive volunteers. In these concentrated fractions we were able to demon¬
strate both a dose-response curve for ATPase inhibition as a function of the
concentration of the extract, and displacement of radiolabeled digoxin from three
different rabbit anti-digoxin sera [13]. These data support the view the endogenous
ATPase inhibitor is associated with a cardiac-glycoside-like moiety. The degree of
displacement varies markedly, however, between different antisera. This finding
highlights the danger of attempting to quantify the apparent concentration of the
digoxin-like factor in molar terms.
The inhibitory capacity of the serum eluate was confirmed in the study using
plasma samples from normotensive volunteers and patients with untreated essential
hypertension. In both groups there was a demonstrable inhibition of phosphate
production, although differences in incidence or degree of inhibition could not be
established between the two groups, nor could inhibition be correlated as a direct
function of mean arterial pressure. Quantification of the inhibition is integrally
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dependent upon an inhibition curve of sufficient sensitivity and therefore estima¬
tions as 'ouabain-dose-equivalents' must be interpreted with some caution.
If, as these preliminary results indicate, any differences between levels of inhibi¬
tor in normotensives and hypertensives are extremely small, it would perhaps reflect
the extreme efficiency of such an inhibitor, whereby effective changes in Na+,K+-
ATPase activity could be mediated via extremely subtle changes in apparent
inhibitor concentration or activity.
In conclusion, this study provides a direct demonstration of an endogenous
inhibitor of Na+,K+-ATPase in human plasma from both normotensive and hyper¬
tensive subjects. The technique is simple, reproducible and well-controlled for
potential non-specific matrix effects.
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